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ABSTRACT
Comoglio, Caleb C. M.S.B.M.E., Purdue University, May 2017. Analysis Of The
Efficacy Of Epione Therapies To Treat Phantom Limb Pain. Major Professor: Ken
Yoshida.
The primary objectives of this thesis are (1) to discuss the current understanding
of phenomena associated with, proposed mechanisms of, and suggested treatments
for amputation related pain, (2) to describe the software developed for analyzing
results of a clinical study for the treatment of phantom limb pain (PLP), (3) to
discuss the methods for a multi-center trial by the EPIONE consortium along with
presenting preliminary results, and (4) to discuss the methods and results of a case
study involving a new therapy modality for alleviating PLP. Each objective has been
expanded into a chapter as described below.
Chapter 1 serves as a literature review introducing the topic of amputation, associ-
ated phenomena, and proposed mechanisms. The chapter also discusses the currently
available treatments and the instruments used to measure PLP. Key topics include
the definition of PLP, the prevalence of PLP, current treatment options for PLP, and
experimental measurement of PLP. The final objective of this chapter is to introduce
topics related to the investigation paradigm utilized for the studies following in Chap-
ter 4 and Chapter 5. Therefore, a minor emphasis has been put on surface electrical
stimulation (SES) and operant conditioning.
As with any multi-center clinical study, coordination is key. Chapter 2 introduces
the common clinical protocol (CCP) and methods of analysis for the clinical trials
conducted by the EPIONE consortium. In order to analyze results in an automated
fashion, a software tool was developed. This tool, the EPIONE Extraction Program
(EEP) along with its extension the Group Analysis Module (GAM), is the focus of
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Chapter 3. A high-level overview of the requirements, process flow, and software
testing are described. This chapter also discusses the methods of analysis for several
self-report instruments used to determine effect size in Chapter 4 and Chapter 5. The
outputs of the software tools make up the results presented and described in these
chapters. In addition to the details included in Chapter 3, supplemental information
is available in Appendix A and Appendix B, which are the detailed User Guides for
the EEP and GAM.
Chapter 4 reviews the pilot study data conducted by the EPIONE consortium.
The primary and two secondary instruments used for analysis are discussed. This
chapter provides a brief overview of results from the group. Each clinical site used
slightly different variations of a common clinical protocol to better understand what
effectively drives alleviation of PLP and to allow comparison of results.
The work done at Indiana University - Purdue University Indianapolis (IUPUI)
represents a small part of several other universities involved in the EPIONE consor-
tium. Chapter 5 focuses on a case study at IUPUI with a more in-depth review of
data collected throughout the study period. Using SES, we seek to reverse cortical
reorganization by giving meaningful stimuli through existing circuitry. In this chapter
the present work is discussed by introducing a case study in detail with an analysis
of psychophysical data.
11. AN INTRODUCTION TO PHANTOM LIMB PAIN
With amputation comes many new experiences and sensations. Most credit the
discovery and early characterization of phenomena associated with amputation to
Ambroise Pare´ (16th century) and, nearly 250 years later, Silas Weir Mitchell in 1866
[1,2]. Since then, substantial research has been conducted to further understand the
consequences, mechanisms, and phenomena associated with amputation through the
investigation of physical and psychological changes after amputation. This chapter
has several goals. The first is to introduce the topic of amputation and the associated
sequelae. Second, discuss the epidemiology and several proposed etiologies of the
sequelae, focusing on phantom limb pain (PLP). Third, review methods for measuring
the manifestation of PLP, specifically with respect to psychophysical aspects and
cortical representation. Fourth, explore the proposed treatments of PLP and consider
a potential new therapy paradigm.
Multiple studies have estimated the prevalence of limb loss and the subsequent
effects of amputation. As many as 185,000 amputations occur every year in the United
States [3,4]. It was estimated that 1.6 million Americans were living with the loss of a
limb in 2005, which translates to a ratio of 1:190 Americans; 65% of these individuals
have lower extremity amputations [4]. Fifty-four percent of amputation cases occur
after diagnosis of dysvascular disease, and 70% of amputees with dysvascular disease
(or 38% of the amputee population) were noted to have a comorbidity of diabetes [4].
An unfortunate reality for many amputees is a relatively high rate of reamputation
(26% among those with dysvascular amputation [4,5]). Reamputation refers to those
who underwent an additional procedure or additional procedures to the previously
amputated limb or the contralateral limb within 12 months of the original procedure.
In 1996 U.S. medical care costs exceeded $4 billion yearly for dysvascular amputations
alone [5], which is only about half (54%) of the amputee community [4]. Ziegler-
2Graham et al. predict the number of amputees in the U.S. will reach beyond 3 million
by the year 2050 [4]. This, coupled with the high prevalence of post-amputation
pain (PAP) and the high degree of pain experienced, easily makes the case that
phantom pain is a relevant problem. To further complicate the issue, the amputee
community is ill-informed in regards to PLP; 41.6% of amputees have never heard of
the phenomenon [6].
1.1 Epidemiology and Etiology of Phenomena and Sequelae Associated
with Amputation
Individuals commonly notice the presence of a phantom limb shortly after ampu-
tation. This phenomenon, known as phantom limb sensation (PLS), is the mental
construction of the limb that is no longer present post-amputation. The phantom
limb, or phantom, can be represented in a number of forms, from normal orientations
to those that are not easily described or even physically possible. The phantom can
also present pain to the amputee in many varieties, such as tingling, burning, stab-
bing, etc. This phenomenon is known as PLP or phantom pain. PLP is a subset
of PLS where the sensations specifically cause discomfort. Amputees also experience
other common painful phenomena, such as neuropathic pain (NP) and residual limb
pain (RLP; also known as stump pain). NP is pain due to the damage or dysfunction
of the somatosensory nervous system and RLP is pain in the remaining portion of
the amputated limb. All of these painful phenomena fall under the umbrella of PAP.
1.1.1 Phantom Limb Sensation (PLS)
While the mechanism of the PLS phenomenon is not clear, it is common among
amputees; as many as 80-90% of amputees experience PLS [7–9]. In general PLSs
are localized to the distal region of the phantom, i.e. the hand, foot, fingers, or
toes, and are typically not constant [10]. Rather, the sensations peak intermittently,
sometimes on a monthly basis and sometimes several times a week [9,11]. Sensations
3can be provoked in various ways, such as stump movement, touching the stump, and
urination [8]. In a study involving 255 amputees, 79% reported nonpainful PLS, and
of those individuals 27% (most common) described the sensations as tingling, 26%
as itching, 13% as feeling asleep, among others [9]. Another related phenomenon
is perceived movement of the phantom, where the amputee is able to consciously
move the orientation or sense movement of the phantom. Eight days after amputa-
tion 36% of amputees felt movement of the phantom with 19% feeling spontaneous
movements (i.e. movements that were not consciously driven) [8]. Similarly, another
study by Kooijman et al. found 38% to experience movement [11]. For some am-
putees, electromyogram (EMG) patterns in the stump during imagined movements of
the phantom limb are distinguishable and non-random, indicating hand motor com-
mands are preserved after amputation and there exists an inherent understanding of
how to manipulate/move the phantom [12]. The modulation of signal seen in the
stump did not appear in experiments with the intact limb, which supports current
theories post-amputation reorganization at some level. The efforts to move the phan-
tom were not only observed through muscle movements, but also through peripheral
nerve activity, i.e. Dhillon et al. recognized nerve activity in the residual limb dur-
ing attempted movements [13]. Furthermore, they recognized activity in the central
nervous system (CNS), specifically in the motor cortex, during phantom movements.
These findings emphasize the current understanding of phenomena associated with
amputation; the sensorimotor cortices and related peripheral innervation are actively
involved in the perception of the phantom limb [13].
An altered kinesthesia is also common. For example, as many as 30% of amputees
experience telescoping, which is the gradual shortening or retraction of the phantom
limb, as depicted in Figure 1.1 [8,14]. In some amputees the phantom limb no longer
reflects the original anatomy. In this example the phantom limb shortens and is
drawn into the stump. In these situations the residual limb and phantom hand or
foot are no longer in an orientation that matches the original volume or limb, which
4causes confusion and concern to many amputees. Telescoping has also been linked to
increased levels of phantom pain [15].
Fig. 1.1. The Phantom limb retracts into the stump over time in some amputees.
In some circumstances PLSs can be helpful in adjusting to the use of a prosthetic
device, where the phantom limb embodies the prosthesis [16]. Murray describes
the embodiment phenomenon as a transition of a prosthesis from an extracorporeal
structure to a corporeal one, meaning the prosthesis becomes part of the identity of
self. This fits into the field of psychoprosthetics, which uses a psychological framework
to analyze and explain the phenomena associated with prostheses and the amputation
rehabilitation process. Corporeal embodiment does not occur in all amputees, which is
not well understood. Murray attributes this embodiment transformation to practice,
i.e. increased use of the prosthesis [16]. Despite the possible utility of PLSs, in many
5cases the phantom sensation evolves into the form of PLP, which can be not only
a hindrance, but a phenomenon that has a strong negative effect on the amputee’s
quality of life [17]. The phantom limb can also be debilitating when the sensations
are painful; 54% of amputees who experience painful phantom sensations, or PLP,
regarded the pain as somewhat bothersome (27% said extremely bothersome) [18].
Phantom sensations are not pathognomonic to amputation of a limb [19]. In
fact studies have recognized phantom sensations in other sensory systems. Phantom
eye syndrome has been found to affect as many as 51% of patients with orbital
exenteration with 26% feeling pain [20]. Phantom eye sensations most commonly
came in the form of elementary visual hallucinations such as white light or colored
light and were triggered by darkness, stress, and fatigue, among others [20]. Another
argued case of phantom sensation is tinnitus, where individuals experiences phantom
auditory sensations, most commonly described as ringing in the ears, steady tones,
or hissing [21]. Tinnitus has been linked to hearing loss, i.e. up to 90% of cases are
linked to hearing loss [21]. Like PLS, tinnitus describes false perceptions; however,
tinnitus is unique because it also occurs in individuals who are otherwise healthy.
Sectioning of relevant cranial nerves has not proven successful for the treatment of
tinnitus, lending to support the current proposed mechanism of maladaptive neural
plasticity [21,22].
1.1.2 Phantom Limb Pain (PLP)
The prevalence of PLP, or phantom pain, widely varies in literature. A survey
by Ephraim et al. (with 914 respondents), phantom pain was reported in 79.9% of
amputees with 38.9% reporting the pain as severe (≥ 7 on a 0-10 analog scale) [18].
Ephriam et al. recognized no significant difference of the rates of phantom pain based
on etiology, age, or level of amputation; they also noted that the rate of PLP for upper
limb amputees was 83%, consistent with the rest of the study population [18]. Eleven
percent of the amputees in this study were upper limb (10% unilateral), leaving 89%
6as lower limb (79% unilateral). The mean pain intensity for phantom pain of all
study participants was 5.5 ± 2.6 [18]. Others have found prevalence rates ranging
between 40% and 85% [6, 9, 11, 23, 24]. Various explanations have been offered for
discrepancies in the prevalence, such as response rates and bias from choice of study
population. However, the clear cause of the differences is not known. The range for
PLP prevalence in amputees generally referenced in literature is 50-80%.
The quantification and description of PLP is important in understanding the
effectiveness of treatment. From the standpoint of self-reporting scales, pain can be
defined in terms of intensity, affect, quality and location [25]. Most research studies
have opted to primarily measure intensity and bothersomeness using the visual analog
scale (VAS) or the discrete version called the numeric rating scale (NRS). Average
ratings of pain, in terms of the VAS, fall in the range of 5.1 to 5.5 out of 10 [9, 18].
Ehde et al. found that when asked how bothersome the pain is (scale of 0-10, 0
being not at all bothersome, 10 being as bothersome as could be) 32% of respondents
reported pain as being severely bothersome (≥ 7) and only 10% rated the PLP as not
bothersome at all [9]. Likewise, Ephraim et al. found only 19% of respondents not
to be bothered by the PLP they experienced [18]. Amputees tend to describe PLP
as knife-like (stabbing), sticking, burning, squeezing, etc. [8, 10,26].
A final metric or description of PLP is needed to quantify frequency and length-of-
time of the pain. Efforts have been taken to define how often amputees felt PLP, and
how long the pain was present. Amputees suffering from PLP experience the pain at
different intervals; 31% report a frequency less than 1 episode per month, 14% a few
times a day, and 7% have constant pain [24]. Another study found 14%, 24% and 24%
for the same time frames, respectively [11]. Kooijman et al. found a fairly uniform
distribution among frequencies of phantom pain attacks from feeling PLP a few times
per year, month, week, day and constant pain, ranging from 14-24% [11]. Kern et al.
found of those experiencing PLP, 56.1% have pain lasting less than 5 hours daily and
many (27%) felt pain constantly [6]. Ephraim et al. reported frequency in terms of
never, sometimes, always (20.1%, 58.7%, 21.2%, respectively) [18]. Ehde et al. found
781% of amputees to experience intermittent PLP, between once a week or less and
4-6 times per week [9]. Among these studies the rates are different for frequency of
pain, as shown in Figure 1.2.
Ehde et al. [9] Kooijman et al. [11] Ephraim et al.  [18] Schley et al. [24] Kern et al. [6]
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Fig. 1.2. Various rates have been reported in literature for the frequency of PLP
episodes. Most respondents reported PLP as occurring at a frequency somewhere
between never and always. Several variables could explain discrepancies among
studies, including epidemiology and etiology of amputation, years since amputation,
size of sample population, etc. The effect of these factors on PLP presentation is
not well understood
The median follow up period for the study by Schley et al. was 3.2 years while
the median follow up period for the study by Kooijman et al. was 19.1 years. Also,
the events leading to amputation (i.e. the study population) were slightly different
among studies, where 98% of the Schley et al. data came from traumatic cases [24],
78% from traumatic cases in the study by Kooijman et al. [11], and 50% for the study
by Kern et al. [6]. Conversely, frequency and duration of PLP have also been found
to decrease within 6 months after amputation [10]; this contradicts the discrepancy in
the constant pain rate between Schley et al. (7% at 3.2 years after amputation) [24]
8and Kooijman et al. (24% at 19.1 years after amputation) [11]. It is not clear which
findings are more representative of the general amputee population. Ephraim et
al. found of amputees 10+ years post-amputation; 74% were experiencing phantom
pain [18]. The measure of length-of-time of pain has been reported in several ways,
which makes it difficult to compare among reports in literature. PLP tends to flare
episodically for seconds to minutes, but some have reported pain lasting several hours
to a day or even longer [9, 10,26].
Triggers of PLP
Some have sought to understand the common comorbidities and triggers associated
with phantom pain. Those who indicate a depressed mood are more likely to report
severe pain and pain that is extremely bothersome [18]. Phantom pain comes in
many forms with many triggers. Often times PLP can flare during emotional distress,
stump pressure, urination, cold temperature, or while coughing [8]. Pre-amputation
pain has been recognized in several studies to be associated with phantom pain after
the amputation [8, 10, 24]. Many have suggested a correlation of PLP and RLP;
however, Kooijman et al. suggested that RLP acts as a trigger of PLP [11]. This
claim has not been substantiated by subsequent research. Giummarra et al. suggest
several categories of triggers, the most frequent of which is “Movement and ‘behavioral
schema’ triggers”; these include activities such as scratching an itch, gesturing with
the phantom, etc. [27].
1.1.3 Residual Limb (Stump) Pain (RLP)
A substantial number of amputees experience pain in their residual limb. As with
other descriptors of pain, the rates vary widely in literature. Rates of stump pain span
from 22% - 76% [8,9,11,18,24,28,29]. More recent surveys support rates on the higher
side (61% - 67.7%) [18,24,28]. Ehde et al. reported that, in response to asking which
pain is the worst, the highest rated site (33%) was the residual limb, over phantom
9limb, back, and others [9]. RLP was also found in another study to be more impairing
than PLP or back pain [30]. Only 4% - 13% of amputees experiencing RLP think of
it as not bothersome at all [9, 18]. On average, the intensity of the RLP falls in the
moderate pain range at 5.4 on a 0-10 scale and is commonly described as aching or
burning [9]. This is supported by Ephraim et al., who found that for the individuals
experiencing RLP, the pain was almost uniformly spread among mild, moderate,
and severe (41.8%, 28.3%, and 29.9%, respectively), with mild being slightly more
prevalent [18]. Similar to PLP, RLP tends to present itself in episodes and can
last seconds, minutes, hours, or longer [9]. RLP does not tend to diminish with
time after amputation [18]. Looking for the cause behind the pain is an elusive
question. O’Reilly et al. propose the pain is a result of neuromata [31, 32], which
are sensitive bundles of nerve endings that result from inability to reconnect with
the target tissue [33]. Taken together, the high rate of prevalence and the impact
on the quality of life highlight the degree to which RLP is a debilitating problem
that needs to be addressed. A clear path to treating the issue of RLP is to look at
treatment methods for NP. Neuromata are often associated with this type of pain,
since inherently neuromata are a result of damage to the Peripheral Nervous System
(PNS).
Amputees, often times, cannot distinguish between PLP and RLP [14,34]. Gener-
ally this confusion arises when pain is felt in the vicinity of the amputation site, where
the phantom and residual limbs meet. RLP and PLP tend to correlate, especially in
intensity [26]. Schley et al. found that 86% of amputees experiencing phantom pain
also experienced stump pain [24].
1.1.4 Neuropathic Pain (NP)
NP plays a role in phantom phenomena [19]. Casale et al. suggest that there is
a significant link between neuromata and PLP [7]. Neuromata make the surround-
ing area more sensitive to stimuli (mechanical, chemical, electrical), which explains
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correlations of pain and various triggers (e.g. touch, mood, stress, etc.) [7]. Many of
the descriptors of PLP and RLP reflect what would be expected of NP, i.e. burning,
stabbing, etc., which leads one to conclude that PLP and RLP are forms of NP, and
may link to the development of neuromata in the stump. Neuromata are the most
common cause of pain in one study [31]. However, not all neuromata result in pain.
For example, the same study found 159 neuromata in the sample population, but
only 91 (57%) were painful in response to transducer pressure [31]. Another study
supports this finding with similar rate of pain occurrence at 67% [32]. Furthermore,
when neuroma excision is not always successful. In a small case study neuroma
excision relieved pain in only two of the six patients [35]. On the other hand, retro-
spective studies of neuromata removal found surgery to be a very successful method
for relinquishing pain [36,37]. Nevertheless, even though the links among neuromata,
PLP and RLP are uncertain, it does not rule out that PLP and RLP arise from NP
origins. Nikolajsen et al. found a link of PLP to N-methyl D-aspartate (NMDA)
receptors through treatment with ketamine and concluded that PLP and RLP have
mechanisms linked to both peripheral and central systems [38]. NMDA is an excita-
tory neurotransmitter which interacts with NMDA receptors. NMDA receptors are
known to be associated with neural plasticity, having a role in long term potentiation
and long term synaptic depression. They are also involved in sensory transmission;
A-delta and C fibers use NMDA receptors among others in transmitting painful stim-
uli up nociceptive pathways at synapses in the Rexed laminae of the dorsal horn [39].
Furthermore, having these roles gives way to one of the current, proposed mecha-
nisms for NP, which points to NMDA receptors as a culprit for injury-induced central
sensitization leading to secondary pain presentations such as allodynia and hyper-
algesia [39, 40]. For this reason, as discussed later, NMDA receptors are a popular
target for medicinal treatment approaches to alleviate NP [40].
Whereas, PLP is pain in the phantom and RLP is pain in the stump, linking
the two to NP offers an explanation that neither form of pain would exist without
injury to the PNS. This also assumes that RLP and PLP are not generated through
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traditional means of activating nociceptor pathways. Although, this theory does not
explain all observed conditions of phantom pain, e.g. people who are congenitally
limb-deficient. As many as 20% of these individuals experience phantom limbs at
some level (either sensation or pain), even though there is no injury, per se [41].
1.1.5 Secondary Effects of PAP
It is not just the rate of amputations and the severity of the pain that makes this
problem relevant, but also the impact of PAP on an individual’s every day life. The
multifaceted attack of PAP through various mediums, such as PLP, RLP, and other
forms, interferes with daily activities [30]. Amputation and PAP negatively affect the
self-perceived quality of life through fatigue and diminished mood [42]. This leads to
high rates of depression among amputees (as high as 41%) presenting a vicious cycle,
as there are substantial links among depression, level of pain, and bothersomeness
of pain for PLP and RLP [18, 43]. Depression secondary to amputation could be
remediated by educating the population on the risks of amputation and providing
mental health services [44].
1.2 The Proposed Loci and Mechanisms of PLP
1.2.1 Neurologic Locus of PLP
The root cause of PLP is not clear as effects of amputation appear in each level
of the nervous system, indicating multiple compounding sources of pain. Evidence
suggests that PLP is the result of a multi-faceted, combined system response from
cortical, peripheral, segmental, and even psychological origins [15]. Most propositions
of mechanisms discuss cause and effect on the level of the CNS or PNS. Because of the
many proposed mechanisms, further partitioning is necessary. Therefore, mechanisms
are discussed below according to the relevant neurologic locus: peripheral, spinal,
supra-spinal, and cortical [15,45].
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Predominant Mechanisms of the Peripheral Neurologic Locus
The Tinel sign (also “tingling” sign) was originally proposed to identify regions of
peripheral nerve regeneration, specifically regarding cases of nerve injury [46]. Sim-
ilarly, one can use the Tinel sign on an amputee to locate nerve injuries that cause
sensations or pain in the stump or phantom (referred sensation or RS). Commonly,
the location that causes sensation or pain is at the site of a severed nerve, which
has morphed into a neuroma. These neuromata (known as terminal neuromata) are
typically formed within 1 - 12 months after nerve transection [47], but start to form
within hours [33]. A study in rats found that ectopic discharges from injured pe-
ripheral nerves have a role in initiating NP, but do not have a significant role in the
maintenance of NP [48]. The onset of ectopic discharges is correlated with the onset
of allodynia (pain from a stimulus that would normally be nonpainful) shortly after
nerve transection, indicating these are responses to or results of injury [48]. However,
in animal studies ectopic discharges diminished over time, while tactile allodynia was
maintained [15, 48]. These circumstances in the periphery seem to demonstrate two
effects of nerve transection, but do not identify the source or mechanism of pain.
For example, neuromata have been found to be sensitive to mechanical and chemical
stimuli [15,33], so much so that PLP can be heightened from tapping [49]. However,
a study on two amputees found that PLP persisted even after blocking PLP asso-
ciated neuromata with lidocaine [49]. This causes further suspicion that PLP and
other phantom phenomena are not caused by peripheral mechanisms; rather, they
are merely accentuated by peripheral factors.
Predominant Mechanisms of the Spinal Neurologic Locus
Deafferentation of the dorsal horn is thought to be linked to PAP, specifically
through central sensitization, which is the increased activity of the dorsal horn afferent
targets due to decreased suppression from the brainstem [45, 50]. Deafferentation
could be a result of amputation, or it could be another type of injury such as brachial
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plexus injury. Jensen et al. proposed that pain may be induced from atrophy of
deafferented dorsal horn neurons and changes to receptive fields in the spinal cord [8].
Spinal reorganization has also been recognized in functionally inactive regions and
is reversible if the relevant nerves regenerate [45, 51]. It has also been manipulated
through operant conditioning of spinal reflexes (a well known mechanism for learning).
Thompson and Wolpaw reviewed several studies that took advantage of the operant
conditioning paradigm to alter reflexes [52]. Because of the integration of sensory
information in the spinal cord (especially connections involved in gating through
suppressive inhibitory interneurons), spinal mechanisms are important to consider
[53].
Predominant Mechanisms of the Supra-spinal Neurologic Locus
Florence and Kaas found in animal studies that cortical reorganization was linked
to reinnervation and sprouting afferents subcortically in the brainstem and thalamus
[54]. Some have linked amputation to significant changes to the cuneate nucleus
in the brainstem, which typically projects to the thalamus and transmits afferent
sensory information, especially from the hand [54, 55]. Xu and Wall found changes
in the cuneate nucleus to occur within minutes to hours after injury in primates [56].
Further evidence of supra-spinal reorganization was demonstrated in adult squirrel
monkeys [57]. Churchill et al. found that somatotopic reorganization of the thalamus
and brainstem was of a similar extent to what is reported for the cortex [57].
Predominant Mechanisms of the Cortical Neurologic Locus
A traditional theory, as proposed by Ramachandran et al., is that cortical reor-
ganization is the primary mechanism of PLP, which is typically discussed in terms
of plasticity of the primary somatosensory cortex (S1) [58, 59]. Directly following
amputation, the mapping of S1, i.e. Penfield’s Homunculus, no longer matches the
anatomical structure. Changes occur in the sensory and motor cortices adapting to
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both the altered anatomy and the loss of sensory input [59]. Specifically, the plastic-
ity of the cortex allows neighboring regions of the somatosensory homunculus to take
over the region that previously mapped to the, now deafferented, limb [58]. However,
this mechanism also has missing links when looking at clinical experiences. A case
study of two amputees found that some experience RS in the phantom hand while
touching the ipsi- or contra-lateral foot [60]. Another study found RSs in the upper
leg and genitals that mapped to the phantom in upper limb amputees [27]. Flor et
al. found significant differences in activity among amputees experiencing phantom
pain compared to those not experiencing PLP in regions such as SI, the secondary
somatosensory cortex (S2), and the posterior parietal cortex (PPC) [59]. Other cor-
tical changes have also been evaluated, such as unmasking of pre-existing synapses
of neighboring cortical regions, e.g. of SI, and of pre-existing trans-commissural con-
nections, e.g. for coordinated movements of multiple limbs [61]. The latter is of
particular interest because it may explain cortical reorganization ipsi-lateral to the
amputation as seen by Schwenkreis et al. [62, 63].
Referred Sensation and Related Mechanisms. While all phantom sensa-
tions are in a sense “referred”, the definitions of PLS and RS are slightly different.
PLSs are generally understood to be any sensation felt in the phantom limb, whereas
RSs are perceived feelings in a body part when another body part is being stimu-
lated (such as the residual limb or the face). RS is a common occurrence in am-
putees [58, 59]. While it is possible to feel RSs without nerve injury by stimulating
proximal regions of a peripheral nerve as demonstrated by Forst et al. [64], RSs typi-
cally are amplified in amputees (i.e. more regions of the body such as the face and ear
map to the phantom limb). Similar to amputation, substantial RSs have been noted
in individuals with type I complex regional pain syndrome (CRPS) [65], spinal cord
injury [66, 67] and other nerve related ailments. As with other aspects of phantom
phenomena there is debate on the mechanism of RSs. This phenomenon is thought to
originate from mechanisms that are separate from other phantom phenomena, as they
are non-neuropathic in nature [19]. Flor et al. found correlation of RSs to increased
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activity of the PPC [59], while Ramachandran et al. supported reorganization of S1
to be the primary mechanism [58]. Stimulation of the remaining nerve in the residual
limb has also elicited RSs; Dhillon et al. achieved this through stimulation with im-
planted electrodes [13]. Similarly, Forst et al. were able to evoke RSs through surface
electrical stimulation in healthy subjects by placing surface electrodes over the ulnar
and median nerves [64].
The mapping of RSs requires the analysis of three primary locations: (1) the
area being stimulated, (2) the area being referred, (3) the cortical location of so-
matosensory processing. Several questionnaires call for a subject to locate the areas
of pain [68], but because non-painful sensation are generally not bothersome [29],
the location and mapping of RSs has not been addressed except cortically. This is a
useful measure to determine changes in the presentation of pain. RSs can be evoked
by touch; the Tinel sign is a simple method for identifying these regions [46,69].
Several interesting phenomena, which likely have different mechanisms, are con-
sidered RSs. For example, the RSs evoked by touching the face of an amputee (as
done by Ramachandran et al.) likely has a mechanism primarily in the cortex [58,59].
However, an RS evoked from stimulation of the proximal region of a peripheral nerve
(as done by Dhillon et al.) likely can be explained by peripheral and/or spinal mech-
anisms [13,64].
Psychological Aspects of Pain
Emotional and psychological states have a large role in interfering with amputees’
lives [43, 70, 71]. The initiative on methods, measurement and pain assessment in
clinical trails (IMMPACT) recommends testing effects on emotional functioning when
conducting pain-related clinical trials [72]. Since amputees have exhibited differences
from the general population in this respect, it is reasonable to assume that it also plays
a role in the experience of PLP and other post-amputation phenomena. In general
PLP is not a symptom of psychological distress [73]. Katz and Melzack reported that
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depression and anxiety were not predictors of PLP [74]. This is further supported by
Darnall et al. who found extremely bothersome RLP or PLP lead to increased odds of
depressed symptoms, but depressed symptoms do not necessarily indicate bothersome
RLP or PLP [44]. Darnall et al. concluded that one of the highest risk factors for
depressive symptoms is PAP [44]. Both Hill and Katz cautioned researchers on the as-
sumptions related to depression and PLP saying claims of psychological explanations
of pain are unsubstantiated and study populations may be inherently biased [14,73].
Along the same lines, some have suggested that the causal relationship between pain
and mood is only uni-directional, i.e. negative mood states are a result of pain, but
pain is not a result of negative mood [75]. Even though the relationship of PAP and
depression is still under investigation, the relationship of depression and amputation
seems to be quite clear. In addition to depressive symptoms, evidence of anxiety,
insomnia, and other psychological ailments are prevalent [70]. This demonstrates a
need for mental health services among the amputee population.
1.2.2 “Phantom” Pain in Non-Amputees - a Complicated Issue
The traditional definition of PLP refers to pain in a limb that is not present. How-
ever, there are also instances of sensation and pain in a limb that has lost connection to
the CNS (deafferentation), from brachial plexus avulsion (BPA) or intraspinal injury
for example. These scenarios have been dubbed as “phantom” because the individual
does not experience pain or even sensation through typical nociceptive and sensory
pathways, because they are no longer connected. In this regard “phantom” sensa-
tions have been found in individuals who have brachial plexus injuries [76–78]. In
addition to the similar descriptions of pain, after BPA individuals experience RSs in
the deafferented limb from touching the ipsi-lateral face [77]. Brachial plexus injuries
also lead to cortical reorganization [79]. Most often pain is described as tingling,
pins and needles, burning, sharp, or paroxysmal [80], which is reason to believe BPA
causes NP [53]. The underlying mechanisms of pain as a result of BPA are not well
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defined. In comparing symptoms one must consider that brachial plexus injuries are
often incomplete, meaning the limb remains partially sensate because it is still par-
tially neurologically intact. If individuals with BPA or intraspinal injury experience
PLP, the phantom pain and phantom sensations convolute with trace sensations from
the limb. Furthermore, the presence of the limb further complicates discriminating
phenomena as phantom or not. While the pain presents in a similar fashion to that
of pain as a result of amputation, the presence of the limb makes it difficult to know
if the mechanisms are the same.
1.2.3 Theories of Why PLP Presents
In the study of phenomena associated with amputation, an important thought to
consider is that a single mechanism will likely not explain all phenomena. This idea
was proposed by Sherman et al. in their evaluation of the mechanism of PLP, which
concludes that different presentations of pain should be treated differently clinically,
but does not suggest how [81]. Several theories have been proposed over the years to
explain PAP and phantom phenomena. Ronald Melzack and Patrick Wall have had
many contributions to this list and evolution of theories including the Gate Theory
of Pain, the Neuromatrix theory, and others, which are discussed below.
Gate Theory
Gate Theory is a prominent pain theory developed in the 1960s [82]. The concept
in its most basic form can be summarized as a complex multi-input, multi-layered
system, where inputs at various layers can relay “off” or “on” signals, which cascade
to determine whether or not pain is perceived [82,83]. More specifically, Gate Theory
suggests that portions of the dorsal horns, such as the substantia gelatinosa, and the
brain are active contributors to the system, which excite, suppress, and modulate
signals to downstream targets [84]. Wall reinforced the theory after a few years
discussing new findings in the field and how they relate to the previously proposed
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theory [85]. In development of the theory there were many unknowns as to how
the theory was implemented physiologically. In returning to the topic Wall proposed
that descending control involves the periaqueductal grey matter and nucleus raphe
magnus [85]. The theory was proposed ahead of its time, pushing the field forward
to better understand mechanisms of pain [83]. Since its introduction, Gate Theory
has evolved over several decades to account for new findings [83, 85]. It provided
the framework for future theories of mechanisms that incorporate the CNS and an
individual’s unique life experiences [14, 84]. Melzack proposed a new theory as a
derivative from Gate Theory called the Neuromatrix Theory, which emphasizes a
sense of self in the perception of pain [84].
Neuromatrix Theory
The Neuromatrix Theory relies on the concept of a network of neurons that de-
fines a genetically determined feeling of self [86, 87]. The neuromatrix is thought to
extend beyond the somatosensory areas of the cortex to the limbic and thalamocor-
tical systems [61]. Melzack proposed the neuromatrix could be molded by sensory
input and is comprised of “thalamocortical and limbic loops”, which cyclically process
and synthesize input and output patterns. These patterns are what Melzack deemed
the neurosignature, an individual’s pattern of synaptic connections impressed on the
neuromatrix [87]. An altered neurosignature, due to amputation for example, would
result in the experience of a phantom limb through sensations and possibly pain [34].
The Neuromatrix Theory considers sensory input and transmission on a “level of
equal importance” as hormonal mechanisms of stress, meaning pain does not exist
solely in a space of neural mechanisms, but also has psychological factors [87]. The
diffuse nature of the theory, i.e. pain (or even phantom sensation) being the output
of a large, complex psychophysical system, makes it difficult to isolate and test clini-
cally [14,34,61]. Furthermore and even more perplexing, the theory does not offer an
explanation for why some amputees experience phantom pain or phantom sensation
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and others do not [34]. Giummarra et al. offer examples of seven phantom limb
related experiences that are not explained by the Neuromatrix Theory and concludes
that Neuromatrix Theory may provide explanations of PLP, but not PLS [61]. While
Neuromatrix Theory is intriguing and will likely spark discovery in the current age
of pain research (like Gate Theory did in the 1960s), it lacks some explanation for
phantom phenomena.
Mal-adaptive Cortical Plasticity
The idea of mal-adaptive cortical plasticity is that the sensorimotor cortex reor-
ganizes in a way that causes pain post-deafferentation. Whereas it is clear that the
cortex reorganizes post-amputation, the extent of the relationship between reorgani-
zation and pain is unclear [15]. Evidence supporting this theory compared hand and
lip movements among upper limb amputees and healthy controls, where amputees
experiencing PLP showed reorganization of the mouth and hand region of S1 and the
primary motor cortex (M1) [88]. In a study of brain-machine interfaces with patients
experiencing phantom pain, Yanagisawa et al. found that attempting to merge and
amplify neural signaling to cortical representation of the phantom actually increased
pain [89].
Pain Memory
The pain memory hypothesis supposes that phantom pain mimics pre-amputation
pain because of implicit pain “memories” established in the somatosensory system [15,
34]. The hypothesis relies on plasticity of the somatosensory cortex due to nociception
[15]. In a small study involving capsaicin injection, sensitivity of SI to nociception
has been measured, improving validity of the hypothesis [90]. Further support for the
hypothesis is that phantom pain commonly embodies pain that was experienced pre-
amputation [74], and several studies have found correlations between pre-amputation
pain and phantom pain [8,91]. However, this theory does not account for the amputees
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who experience PLP but do not experience pain pre-amputation. Furthermore, some
amputees feel pain due to the phantom limb being in an unnatural or biologically
impossible orientation, which does not support this hypothesis.
Sensory Confusion
The hypothesis of sensory confusion assumes that pain is a result of ramping due to
broken feedback mechanisms. While feedback loops exists sub-cortically, evidence also
points to involvement of frontal and parietal brain areas in the “incongruence of motor
intention and sensory feedback” [15, 92]. Similar to Gate Theory, this hypothesis
relies on closed-loop control of peripheral and central mechanisms, which modulate
sensorimotor information during movement. Harris compares this effect to the feeling
of nausea when senses do not agree on body position or balance [92].
1.3 Measuring PLP
Pain has both behavioral and physical properties and can be largely subjective.
Intensity, affect, quality and location are the primary experiential dimensions of pain
[25]. Pain intensity refers to the extent of the pain and can be subjective based on
historical experience of the individual reporting the pain. Pain affect refers to the
“emotional arousal or changes in action readiness caused by the sensory experience of
pain,” as so eloquently put by Jensen and Karoly [25]. In essence pain intensity refers
to the extent of pain while pain affect refers to the emotional experience related to pain
or the extent to which the individual is bothered by the pain. Pain quality refers to
the descriptors of pain with respect to sensation, such as tingling, burning, sharpness,
etc. and also includes the time-related aspects of pain, such as frequency, length-of-
time of pain, etc. Pain location defines the area pain is perceived. Each of these
four dimensions of pain are important to measure when studying the effectiveness of
treatments and therapies for PLP. However, the measurement of PLP is a complicated
issue. When measuring pain in a research setting (clinical or animal), there are
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additional considerations, such as the effects of habituation and sensitization [93].
Because of these barriers, pain-researchers utilize multiple measures and consider
behavioral presentations of discomfort in analysis [94]. Across studies of proposed
therapy methods, various pain measures and scales have been utilized; in regards to
PLP, studies tend to describe the degree of pain and the extent the pain interferes
with the individual’s life through various psychophysical measurement modalities [14].
This variety of methods makes comparisons of results difficult.
1.3.1 Psychophysical Measures of Pain
In order to understand the effects of a given therapy modality, one must measure
the various aspects of pain. Several validated measures are available to do this. The
instruments used in the present study for effect determination are the visual analog
scale (VAS), neuropathic pain symptom inventory (NPSI), profile of mood states -
short form (POMS-SF) and are discussed below. These were chosen because of the
sensitivity they have shown in previous studies, but also because they are validated in
the languages being used by the EPIONE consortium, i.e. Danish, English, French,
Italian, and Swedish. The primary measure of effect and two secondary measures
are introduced below and are utilized for analysis in Chapter 4 and Chapter 5. In
addition, an exploratory measure, the brief pain inventory-interference scale (BPI-IS),
is discussed below, which is shown in Chapter 5. These four self-report questionnaires
are the focus of the EPIONE Extraction Program (EEP) and Group Analysis Module
(GAM), which is introduced in Chapter 3. More details for these instruments are
included in Chapter 2.
Self-report Questionnaire
While self-report questionnaires are an obvious way to gather information and
understand the pain being perceived, the subject to subject (inter-subject) variation
cannot be predicted. For example, Dar et al. found, in a small study of injured vet-
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erans, that severely injured individuals have a higher pain tolerance and higher pain
threshold than lightly injured individuals [95]. In a study of thermal pain thresholds,
Wasner et al. explored preconditioning as a means of testing sources of inter-subject
variations; however, in terms of pain thresholds, the study found no difference in sub-
jects who were preconditioned and subjects who were not preconditioned [96]. This is
a relevant finding because of the concern for scale recalibration presenting a potential
source of variability in self-report data. The proposition of scale recalibration is an
issue that is not addressed in the realm of PLP. However, in other research areas,
this has not been validated as a source of variation. Lacey et al. found no evidence
of scale recalibration in individuals suffering from chronic illness (specifically with
regards to quality of life ratings) [97]. Nevertheless, studies typically rely on vali-
dated instruments and assessments to characterize pain and understand the effects of
a given treatment for a population.
The Visual Analog Scale (VAS)
Psychophysical measures involve those that describe an individual’s perception. A
commonly used instrument is the VAS. With respect to pain intensity, an individual
experiencing pain ranks the pain somewhere between “no pain” and the “pain as bad
as it could be” by marking a line spanning between the two extremes (commonly
separated by 10-cm). The individual’s severity of pain can be enumerated by mea-
suring the length from 0 (no pain) to the marking [94]. The primary measure of most
studies describing the prevalence of PLP is typically some version of pain intensity;
most often this is done with the VAS [14]. The VAS and the discrete version, NRS,
can be used for any measure in which there are two extremes. The VAS has been used
to understand other aspects of phantom phenomena, such as intensity of PLS [23],
and it can be useful in describing the effect of a treatment or therapy. In fact it
is used frequently outside of the realm of PLP [94]. When describing the intensity
of phantom pain, the VAS is often used along with the interpretation or adaptation
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into mild, moderate, and severe pain. Jensen et al. attempted to standardize these
descriptors to pain ranges, 1-4, 5-6, 7-10, respectively, by considering factors such as
pain interference and impact on quality of life [98].
The Neuropathic Pain Symptom Inventory (NPSI)
The idea of using a VAS or NRS has been adopted and adapted to quantify other
unmeasureables because of its dependability [94]. The NPSI utilizes several NRSs
to quantify the qualities of NP [99]. Ultimately, the responses are combined to form
subscores, which represent different aspects of NP, i.e. burning, pressing, paroxysmal,
evoked, and paresthesia (or dysesthesia), and overall NP. In the case of NPSI, pares-
thesia/dysesthesia are defined by the same subscore, which is related to feeling pins
and needles and feeling tingling [99]. The usefulness of the NPSI is that it not only
demonstrates the presence of NP, but also the presentation of the pain. Having this
capability offers the opportunity to study the effects of treatment on subtypes of NP
as well as the effects on overall NP. Mackey et al. proposed extracting information
on NP from the short-form McGill pain questionnaire (SF-MPQ; discussed further
in subsection 1.3.2); this method takes advantage of an existing questionnaire, but it
is not as specific as other measures, such as NPSI [100]. Other measures specifically
related to NP exist, such as the neuropathic pain scale (NPS) [101], the neuropathic
pain questionnaire (NPQ) [102], the “neuropathic pain four questions” (DN4) [103],
the Leeds assessment of neuropathic symptoms and signs (LANSS) [104], among
others; however, these alternative instruments are either not strongly validated, not
detailed enough, or are designed to differentiate non-NP from NP and not to assess
NP [99]. The NPSI has been validated in several languages among various popula-
tions [99,105,106]. A German study found NPSI test-retest reliability to be subopti-
mal [105], compared to the original study [99]. Although, in the German study the
time lag was 24 hours (compared to 3 hours in the original study [99]). While this is a
notable finding, it does not change the validation of the instrument as it is reasonable
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to expect changes in the presentation of pain in a 24 hour period; temporal variation
is a known characteristic of NP [107].
The Profile of Mood States-Short Form (POMS-SF)
In traumatic lower limb amputees, the prevalence of depression was 41.6% [43].
In a broader population base of various etiologies, significant depressive symptoms
were seen in 28.7% [44] (compared to 4.9% point prevalence and 17.1% life-time
prevalence in the general population [108]). Ephraim et al. aptly noted the correlation
of depression and the presence of PLP, where increased pain intensity corresponded
to heightened depressive symptoms [18]. The finding suggests that there is a need to
continuously monitor and swiftly treat depression in amputees [18]. In a more general
sense, mood correlates to the intensity and perception of pain greatly [75]. Some
attempts have been made to treat pain using the class of drugs called antidepressants
and through psychological treatments of pain [107, 109]; however, these have been
ineffective [110]. Mood does not act as an effective target for treatment. However,
it may act as an indicator of positive or negative effect because of its correlation to
pain.
The POMS-SF is comprised of 37 descriptors of mood. Each descriptor is ranked
by the study subject on a 5-point scale (1=“Not at all”, 5=“Extremely”) and is
incorporated into a subscale, which can be used to characterize the individual’s mood.
The subscales are depression, vigor, confusion, tension, anger, and fatigue. Whereas
depression has been shown to positively correlate with pain, other mood descriptors
could provide more insight on the relationship of PLP and psychological state.
The Brief Pain Inventory - Interference Scale (BPI-IS)
The brief pain inventory (BPI) has been adapted into a more succinct question-
naire as the BPI short form (BPI-SF), which is a validated instrument for pain inter-
ference [111–113] The final series of questions is known as the BPI-IS. Questions are
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non-specific to phantom pain and describe how pain has interfered with daily living
over the past 24 hours. The 7-question interference scale utilizes 11-item NRSs to
describe pain’s interference with general activity, mood, walking ability, normal work,
relationships with other people, sleep, and enjoyment of life. The NRSs span from 0
(“Does not interfere”) to 10 (“Completely interferes”).
Problems with Measuring PLP and Other Phantom Phenomena
One factor not addressed by Jensen et al. when describing the standardization
of the VAS with respect to PLP is the associated anchors of the VAS [98]. Anchors
are defined as the descriptions of the minimum and maximum scores. Jensen et
al. used a scale of 0 − 10 with anchors of “0 = no pain” and “10 = pain as bad
as it could be” [98]. A prime example of this inconsistency in research related to
PLP can be found in reports of the intensity of pain. In Table 1.1 several examples
demonstrate how intensities are reported among various authors. The outcome of
not utilizing a standard instrument for measuring pain intensity is data that is not
directly comparable. While it may be possible to normalize the various scales back
to the standard scale proposed by Jensen et al., correlations have not been proposed
among the various scales.
Table 1.1. Different anchors for the VAS make pain intensities difficult to compare
across studies.
Article Authors Pain Scale Anchors
Sherman and Sherman [23] 0− 100 Anchors not described
Montoya et al. [26] 0− 10 No pain / Unbearable pain
Smith et al. [29] 0− 100 Extremely mild / Extremely intense
Ehde et al. [9] 0− 10 No pain / Pain as bad as it could be
Marshall et al. [30] 0− 10 No pain / Pain as bad as it could be
Ephraim et al. [18] 1− 10 Mild pain / Extremely intense pain
Schley et al. [24] 0− 100 Anchors not described
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Furthermore, interpretation of changing VAS scores is non-trivial. Jensen et al.
suggest that a change in pain intensity from “7 to a 4 might be considered more
beneficial and more clinically relevant than a reduction from a 4 to a 1, at least
in terms of the impact of the treatment on function and quality of life [98].” This
conclusion suggests that both the change in pain intensity as well as the baseline or
reference pain intensity are important factors to keep track of in establishing effective
treatments and therapies. In the present study multiple modalities are explored
using a common clinical protocol, discussed further in Chapter 2. The format of
psychophysical measures, including details such as anchors, is consistent allowing
direct comparability of effectiveness.
1.3.2 Other Proposed Self-Report Measures of PLP
Because of the lack of standardization, several questionnaires and instruments
have been developed or adapted for measuring PLP. Hill notes in a literature re-
view of PLP, the McGill pain questionnaire (MPQ) and SF-MPQ have been used
in several studies [14]. The McGill pain questionnaire and its variants have signifi-
cantly contributed to the understanding of pain (in general) and PLP, and it acts as a
primary instrument in many pain studies [114]. Alternate measures of depression in-
clude the Center for Epidemiological Studies - depression questionnaire (CES-D) [18].
The chronic pain grade (CPG) [9, 30, 115] distributes an individual’s pain into one
of four grades based on intensity and disability associated with pain. Grade I is the
least intense and least disabling, while Grade IV is the most intense and most dis-
abling [115]. Flor et al. and Montoya et al. used a 122-item phantom-and-stump
phenomena interview as a primary instrument [26, 116]. The interview is a com-
pilation of several standard instruments to separately analyze stump and phantom
sensations and pain, including a modified version of the MPQ, several VASs to de-
scribe average pain severity and intensity of non-painful sensations, descriptors of
sensations, along with several open-ended questions [26]. Montoya et al. also utilized
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the West Haven-Yale multidimensional pain inventory (MPI) to evaluate the severity
and interference of stump and phantom pain [26]. Smith et al. [29] used the pros-
thesis evaluation questionnaire (PEQ; developed by Legro et al. [117]). The PEQ
highlights intensity, frequency, and bothersomeness of phantom, stump, and back
pain as well as phantom sensations [29]. Further evidence of lack of standardization
is that study designs have opted to utilize self-designed questionnaires such as the
Groningen questionnaire problems after arm amputation (GQPAA) by Kooijman et
al. [11]. Ultimately the choices of questionnaires in the present work came down to
a criterion of language. In order to accommodate all of study sites, the partners of
the EPIONE consortium opted to use the VAS, NPSI, and POMS-SF as the primary
and secondary instruments.
1.3.3 Measuring Cortical Reorganization
Cortical plasticity or cortical reorganization is a popular topic in the study of
post-amputation phenomena. This is mainly because of the desire to understand
the underlying mechanisms. While plasticity is not unique to the cortex [54], it gets
particular attention because of the relationship of the somatosensory mapping and
observations of RSs in the facial region [58]. From the perspective of characteriza-
tion, studies have investigated the differences in cortical activity among amputees and
healthy controls. Lotze et al. studied the locus of activation for hand and lip move-
ments using functional magnetic resonance imaging (fMRI), comparing amputees with
PLP (n=7), amputees without PLP (n=7), and healthy controls (n=7) [88]. Reorga-
nization of the hand and lip areas in M1 and S1 was recognized in patients with PLP
but not others. Many studies have also investigated the cortical differences between
the activities utilizing the affected limb versus the individual’s healthy limbs. This
paradigm attempts to have an individual serve as his or her own control. Measure-
ment of changes to the cortex can be done through several modalities. Blood oxygen
level dependent (BOLD) fMRI is used most often because of the ability to relate ac-
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tivation to particular cortical structures. Most studies that use event-related BOLD
fMRI to look at cortical reorganization focus on S1 and M1 [88, 116]. Other instru-
ments include electroencephalogram (EEG) coupled with some type of somatosensory
evoked potential (SEP) in the periphery, such as tactile evoked potential (TEP) or
laser evoked potential (LEP) [59,118]. Coupling both EEG and MRI, Flor et al. used
EEG to record cortical activation during RSs elicited by TEP, and used the activation
map to overlay an anatomical image captured via magnetic resonance imaging [59].
Some disadvantages should be considered when using BOLD fMRI to study corti-
cal differences. The main disadvantage is the length of time required for measurement.
BOLD fMRI contrast relies on the hemodynamic response function (HRF), which is
an increase in oxygenated blood (specifically oxyhemoglobin) compared to a resting
state. The underlying assumption is that the increase in blood in a particular region
is a causal, time-delayed effect of increased neuronal activity. These details reveal a
reason behind the intensive time requirements of fMRI, as stimuli do not elicit in-
stantaneous responses. Beyond the time dynamics of the biological system, the larger
contributor to lengthy experimentation paradigms are issues of signal-to-noise ratio
(SNR). To alleviate the poor SNR, fMRI paradigms typically utilize signal averaging,
thus longer measurement times. Analysis of fMRI results involves an understand-
ing of both estimation efficiency (ability to estimate the HRF) and detection power
(ability to detect activation) as described by Liu and Frank [119, 120]. Furthermore,
a recent study attempting to validate fMRI statistical analysis methods found high
rates of false positives [121].
1.3.4 Pros and Cons of Different Measurement Approaches
If relating back to the four primary dimensions of pain (intensity, affect, quality,
and location), various instruments have positive aspects and points of weakness. For
this reason several research studies have implemented multiple instruments. Depend-
ing on the study design this could have different effects on self-report data. Thorough
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questionnaires and interviews (such as the MPQ or the phantom-and-stump phenom-
ena interview) allow for detailed description of the pain, but take substantial time and
concentration for the study participant. This could cause frustration and bias if the
participant is enrolled in a study of temporal effects of treatment and having to com-
plete a questionnaire multiple times, for example. Substantial effort should be taken
to consider the length of time a study participant spends responding to questionnaires
and the number of times a study participant responds to a particular questionnaire.
On the other hand there are disadvantages of being too brief [25]. Brevity is just one
consideration in the list of primary trade-offs, where targets should be set to reduce
the required contact time between the health care provider (HCP) and patient, while
maximizing the collection of relevant pain characterization data.
1.4 Current Treatment/Pain Management Methods
The proposition of treating PLP has been under study for decades. In 1980
Sherman et al. reported on 68 different possible methods [122, 123]. To this day a
concise method for treatment has not been identified. Flor suggested more than 30
commonly used treatments for PLP in 2002, only a small fraction of which have shown
any success in randomized controlled trials (RCTs) [34]. Ideally, treatment methods of
PAP and phantom limb phenomena would be developed from a mechanistic approach,
i.e. the mechanism of pain would be utilized to address and reverse the pain. Since the
mechanisms are not well understood, therapies tend to treat the symptoms, leading
to a high number of available treatments, low rates of success, and high rates of
dissatisfaction among patients [122, 124]. Current treatments of PAP can be broken
down into medicinal and non-medicinal methods. Medicinal treatments of pain utilize
various methods of application: topical, oral, and local injection. A wide variety of
non-medicinal treatments have been explored, taking advantage of mechanical and
electrical sensitivity of PAP. Other methods have used traditional pain management
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techniques, while some have ventured into the psychological treatment of pain. All-
in-all treatment of any form of PAP has been largely unsuccessful.
1.4.1 Current Standard of Care
In 1983 a study found that only 17% of amputees were offered treatment for
PLP even though 61% reported experiencing PLP [23]. Potentially, this was because
treatments and therapy were largely ineffective at the time or because the medical
community was not convinced the phantom pain existed or was treatable. Over the
years medical care providers have come to accept the reality of phantom sensation
and pain. Several authors have noted a variety of responses from physicians to those
suffering from PLP such as, “it is in your head” or PLP is “psychogenic [34,125–127].”
Conversely, while the limb may no longer be present, the pain and sensations seem
real. Another study in 1997 found nearly one-third of amputees who discussed PLP
with their doctor were told no treatment was available [128]. Kern et al. attempted
to study the success rates of relevant treatment methods by surveying amputees.
Seventy-one percent (N=537) of the amputees suffering from PLP had never received
or sought after treatment; 19% felt their doctors were incompetent on the topic [6].
Of those who did receive treatment for phantom pain, the treatment with the highest
success rate was opioids via oral or IV administration at 67%. The second highest
treatment method was opioid injection via intrathecal pump at 58%. Neither of these
treat the root problem but only temporarily mask the pain [6]. Whereas the medical
and scientific communities are more accepting of the reality of PLP, the current
standard of care is still up for debate. A focus group of health professionals found
that information given to patients experiencing PLS and PLP is grossly inconsistent,
indicating a necessity for a standard of care to be developed [126].
31
1.4.2 Medicinal Treatments
Medicinal treatments are among the most successful at alleviating PLP. Opioid-
s/Opiates have shown a success rate as high as 67.4% [6], in particular morphine via
injection and oral administration has shown successful reduction of but not elimi-
nation of PLP and RLP in a randomized controlled trial [109, 129, 130]. However,
long-term analgesic efficacy has not been verified [6, 109]. Anticonvulsants have also
shown moderate success (52%) [6]. Gabapentin is a commonly used anticonvulsant,
which has had controversial results in RCTs. Bone, et al. showed reduction of PLP
in comparison to a placebo but no significant change in secondary measures, such
as depression, mood or sleep interference [131]. Conversely, a separate RCT showed
no significant difference between gabapentin and placebo groups [132]. Some side
effects were noted; however, these were not significantly different from the control
groups [131,132].
Alviar et al. reviewed three NMDA receptor antagonists as possibilities: me-
mantine, dextromethorphan, and ketamine [109]. The review identified only ke-
tamine [133] and dextromethorphan [134] to provide pain relief from this class of
pharmacologic interventions [109]; however, both studies were underpowered [109] and
treatment with ketamine had substantial side effects, including dizziness, light hal-
lucinations, and hearing impairment [133]. NMDA receptor antagonists have shown
moderate success at relieving pain. The unsuccessful cases may be related to the
mode of administration; each memantine trial reviewed utilized oral administration
while other studies of this intervention method were successful with injection [109].
Various other options have been explored and proposed for treatment including
antidepressants, calcitonins, and local anesthetics [109]. In patient surveys, antide-
pressants have shown to be ineffective. Only 36.4% noted this method as effective [6].
This ineffectiveness was supported in a RCT of amitriptyline that failed to show pos-
itive results [109, 135]. Furthermore, amitriptyline had a significant adverse effect of
dry mouth over the placebo [135]. Local anesthesia was largely ineffective according
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to patient surveys (21.6% success) [6]; RCTs of intravenous infusion with Lidocaine
have shown successful treatment of RLP but not of PLP [129].
1.4.3 Non-medicinal Treatments
Several non-pharmacological approaches have been proposed and tested as pos-
sible treatments for PLP, such as proper stump management, electrical stimulation,
and mental imagery. Treatments vary significantly in regards to stimulus modality,
psychological demand, and efficacy. Many therapies are proposed in case studies and
uncontrolled trials, but either do not reach the stage of conducting a RCT or are
not successful in a RCT, which makes identifying potential effective treatments in
literature difficult [136]. Some of the more prominent methods are discussed below.
Nerve and Stump Management
Several methods have been proposed to thwart PAP related to neuromata; a
universal method has not been accepted [37, 124]. Proper care of the stump and
preventative measures in surgery are crucial to mediate pain. Painful neuromata are
common among amputees; nearly 30% undergo surgery after amputation with the
hopes of relieving neuroma related pain [6]. Often they form from improper surgical
technique during the original amputation [124]. Studies have shown that simply
excising the neuroma and applying traction to the nerve (encouraging the nerve to
retreat into the stump) is not a successful procedure, only demonstrating successful
results 33% of the time [137]. Over the years several techniques have emerged to
ameliorate this painful phenomenon [124]. A recent review of neuromata treatment
and prevention found nearly 200 techniques, supporting the perfect solution has not
yet been found [124]. Some techniques have proven successful and appear notable;
excision with silicone capping (83% success [138]) or centro-central anastomosis (94%-
95% success [139,140]) are prime examples [124]. On the other hand, techniques such
as these also present unnecessary risks to the patient. Silicone capping involves the
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introduction of a foreign body, which risks immunological response and inflammation
in the stump [37]. Centro-central anastomosis lengthens the time of surgery due to the
meticulous nature of microsurgery, which means more opportunities for infection [37].
One of the most notable techniques is nerve transposition [124]. Mackinnon et al.
demonstrated the capability of minimizing neuroma formation in an animal model
[141]. Rerouting the transected nerve into adjacent muscle without tension, resulted
in significantly smaller neuromata compared to control groups in primate models
[141]. Mackinnon and Dellon revisited the technique emphasizing the importance of
separating the nerve ending from the scar tissue [142]. This study found different
success rate depending on a patient’s previous experience ranging from 56% - 100%
for good or excellent results [142]. The nerve transposition technique had good or
excellent results in 81% of cases (42 patients) [142].
Another method that has had some success is targeted muscle reinnervation
(TMR) [143]. This is the act of intentionally ligating the original innervation of a
nearby muscle to direct alternative peripheral nerves to the muscle. Generally TMR
utilizes a muscle that is no longer providing functional advantages to the patient with
the hopes of the muscle acting as a target for the nerve. The long term goal for
these patients is that they could intuitively move their phantom, which would cause
muscle activity in the targeted muscle; then, this muscle activation could be recorded,
e.g. via EMG, to manipulate an active prosthetic. Conveniently, this method serves
a dual purpose by also preventing the formation of neuromata. In a retrospective
study six months after surgery, the method appears to be successful [143]. All pa-
tients reporting pain reported reduced or eliminated pain, and just under 90% were
able to operate a TMR-controlled prosthesis [143].
Peripheral nerve surgery, such as TMR, is a treatment option for managing pain
related to neuromata that has shown success in several studies, and is an excellent
example of advancement in the field [124]; however, the degree of functionality pro-
vided by this method is often not necessary for lower extremity amputees. Rather
than transferring the transected afferent nerve fibers to an alternative muscle or re-
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gion, some have suggested merely tying the sensory nerves to nearby muscle away
from areas forming scar tissue. If done during the amputation surgery, it could pre-
vent formation and excision of the neuroma post-amputation, thus lowering overall
patient risk through reduction of procedures and procedural time [37]. This proce-
dure, proposed by Ducic et al. as an outpatient operation has had great success
in a retrospective study of 21 neuroma excisions; patients reported an the average
preoperative pain of 8.04 that decreased to 1.07 on the visual analog scale (ranging
0-10) [37]. Furthermore, 85% reported improved quality of life [37]. The key to this
technique involved suturing the nerve-ending (after neuroma excision) to the nearby
muscle. Some have proposed applying light traction to the nerve is sufficient, but an
important detail to many of the techniques is to keep the nerve tension free [124].
Electrical Stimulation
Electrical stimulation of the residual limb, especially transcutaneous electrical
nerve stimulation (TENS) or functional electrical stimulation (FES), has had success
in case studies and small trials. However, as is the case with other therapy methods,
the effectiveness of TENS has not been shown with a RCT [144]. Other forms of elec-
trical stimulation have shown promise as well. Peripheral Nerve Stimulation showed
significant improvement in regards to pain and quality of life, but the study lacked a
placebo and had a small number of participants [145]. Others have attempted apply-
ing TENS to areas other than the residual limb, such as the contralateral limb [146]
and the ears [147]. Both of these methods showed a positive effect in small, short-term
trials, but neither were compared to placebo groups. Sensory discrimination training
using TENS has shown positive results (reduction in PLP and effect in cortical reor-
ganization) in a small comparative study of 10 amputees [148]. This method involved
the application of random, non-meaningful stimulation patterns of varying frequency,
intensity, and location. Trial subjects were instructed to identify different patterns
with the hypothesis that distraction from the pain actually reduces the pain [148].
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Success indicates there is a positive relationship among discrimination ability, cortical
reorganization, and decreased PLP; although, the long term effects of this method
were not reported [148].
Considerations for FES of Peripheral Nerves. Studying the effect in
cats, Agnew et al. found that 8 hours of high-rate, high-amplitude electrical stim-
ulation resulted in irreversible damage of sciatic nerve axons [149]. In an earlier
paper [150], this effect was referred to as stimulation-induced depression of neuronal
excitability (SIDNE). SIDNE, which according to the authors differs from long-term
depression (LTD) because it does not involve a change in efficacy of the synapses
and does not worsen day-to-day, can occur in the CNS if axons are subjected to
“prolonged, high frequency microstimulation [150].” McCreery et al. stimulated the
posteroventral cochlear nucleus (PVCN) for 7 hours per day to find that with high
enough intensity SIDNE could be induced, but was still reversible. The speculated
mechanism attributed the effect to the entry of calcium into the neurons activating
second-messengers and several downstream pathways.
Lu et al. studied the effects of electrical stimulation on peripheral nerve regen-
eration in Sprague-Dawley rats [151]. Methods involved transecting the right sciatic
nerve, separating the nerve endings by 10-mm, and surrounding the nerve endings
by a silicone rubber chamber. Stimulation was applied for 15 minutes every other
day at 1 mA (1, 2, 20, 200 Hz depending on group). Results included histologi-
cal samples as well as tests of nerve conductivity that showed the 2-Hz stimulation
group to have the most mature structure. Lu et al. concluded that in regards to
peripheral nerve regeneration, stimulation (depending on frequency) can have a pos-
itive or negative effects. Note, control group had 100% success in regenerating a
nerve cable spanning the 10-mm gap; however, the conclusion was that the nerves
generated under 2-Hz stimulation were healthiest [151]. Cogan et al. suggest many
culprits when it comes to the cause of tissue damage and that macroelectrodes and
microelectrodes have different challenges when it comes to preventing tissue damage
(especially charge density and charge per phase), but they did not address continuous
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stimulation [152]. Patel and Butera used stimulation frequency of up to 70 kHz to
block nerves, but did not report on the possible effects of continuously stimulating at
these high frequencies [153]. Prodanov et al. [154] reviewed FES in 2003 and pointed
to two other articles by McCreery et al., which also discussed the negative effects of
continuous electrical stimulation [155,156]. The 1995 McCreery paper indicates that
low frequency stimulation does not lead to early axonal degeneration, independent of
stimulus amplitude [156].
Imagery
Mental imagery coupled with various techniques, such as muscle relaxation [157]
or virtual visual feedback [158, 159], present enlightening results that may reveal
psychological aspects of PLP. Ipsi-lateral cortical reorganization could be a target for
mental imagery, especially when utilizing coordinated bimanual movements through
visual feedback [62, 63]. Mental imagery and muscle relaxation showed a significant
reduction in PLP, PLS, and pain interference compared to a positive control group
[157]. The positive control group maintained the same physical therapy schedule as
the test group, while the test group exercised mental imagery, in addition to the
physical therapy. The success of this trial demonstrates an advantage of coupling
physical stimulus with psychological exercise. Graded motor imagery (GMI) utilizes
gradual training in three strategies: (1) implicit motor imagery, (2) explicit motor
imagery, (3) mirror visual feedback [160]. Implicit motor imagery training involves
laterality recognition, or identification of images representing left limbs versus right
limbs; explicit motor imagery practices movement of the phantom limb, or focusing
on consciously manipulating the phantom; and, mirror visual feedback exercises the
movement of the phantom while the patient utilizes visual feedback. Typically, the
visual feedback involves placing the contralateral limb in front of the mirror, the
amputated limb behind the mirror, and simultaneously moving both the contralateral
and phantom limbs. Bowering et al. reviewed studies, including work on PLP by
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Moseley [161], using this multi-pronged approach and found it to successfully treat
chronic pain [162]. While the method has been proposed to treat PLP and PAP, the
effects have not been thoroughly evaluated in this context [163]. Some have compared
the effects of mental imagery through virtual visual feedback (also known as mirror
therapy) to that of TENS when applied to the non-amputated limb [146]. Both groups
showed reduction in pain over a 4-day treatment phase, but neither group performed
significantly better than the other.
This type of mental imagery could be considered a form of conditioning, where
participants actively and consciously reinforce imagined movement with feedback (e.g.
visual or tactile). Imagery is supported by Macuga and Frey [164], who found that im-
agery, i.e. actively simulating movements, stimulates more brain regions than passive
observation. Studies on operant conditioning have shown to alter CNS organization
in the spinal cord, specifically through retraining of spinal cord mediated reflexes [52].
Thus, in these circumstances psychological treatment has physiological implications.
Psychological treatments have had positive results for the treatment of NP in a few,
small studies; however, treatment recommendations for NP have moved toward a
multimodal approach incorporating psychological treatment with pharmacological or
nonpharmacological methods [165]. This serves as a possible opportunity that has
not yet been thoroughly explored in the realm of PAP, through the combination of
psychological and nonpharmacological treatment.
No single treatment method seems to be a superior method for alleviating PLP.
This may be due to the nature of non-mechanism based therapy development, treat-
ing symptoms rather than the root cause. In order to develop successful therapies,
we should first seek to understand the primary mechanisms driving PLP in the back-
ground [45]. We should also seek to understand the effects of various methods by
reporting results in a consistent way. Several studies and the measured effects have
been reported and reviewed; the unfortunate reality is that many of the therapy
methods are difficult to compare in terms of effect because there is not a standard
metric for PLP.
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1.5 A New, Proposed Paradigm for Treatment of PLP
Evidence suggests that therapies should include a level of cognitive involvement
along with physiological stimulation [165]. Through a multi-facet approach the EPI-
ONE consortium seeks to challenge the status-quo of PLP therapy. The multi-center
clinical trial design, as described by Yoshida et al., evaluates several distinct methods
of sensory feedback and reinforces the subject’s RSs with meaningful stimuli during
therapy [166]. Treatment modalities span invasive and non-invasive techniques to
activate the peripheral circuitry, some of which also incorporate the operation of a
hand or leg prosthesis, providing a level of visual feedback, as well. Methods for eval-
uation involve an intensive regimen of psychophysical questionnaires including the
VAS for measurement of pain, along with the POMS-SF, and NPSI, as well as other
exploratory measures. Participants also undergo two fMRI sessions, before and after
the 4-week therapy phase to measure the level of cortical reorganization.
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2. METHODS FOR INVESTIGATING THE EFFECTS OF
COGNITIVELY REINFORCED STIMULATION ON
PHANTOM LIMB PAIN
2.1 Introduction
The methods described in this chapter address the design and implementation
of a multi-center clinical trial for cognitively reinforced stimulation as a treatment
for phantom limb pain (PLP). Crucial details to ensure comparability among treat-
ment groups, such as inclusion/exclusion criteria and data collection methods, are
discussed. Additionally, the methods of assessment to establish the degree of effective-
ness are described. The visual analog scale (VAS), the primary measure, neuropathic
pain symptom inventory (NPSI) and profile of mood states-short form (POMS-SF),
secondary psychophysical instruments, reflect various aspects of pain. The methods
described here were used for collecting and analyzing the data presented in Chapter
4 and Chapter 5.
2.2 Study Organization
Several facets of a clinical trial must be considered to successfully implement the
study. In addition to the treatment modalities, this section outlines the common
clinical protocol (CCP), which ensures the data collected at each site is comparable.
2.2.1 Treatment Modalities
The factors of the experimental design lie within the type of sensory feedback,
which has two primary categories: invasive and non-invasive. The invasive category
utilizes implanted transverse intrafascicular multichannel electrodes (TIMEs) to elicit
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sensation, whereas the non-invasive methods include electrical or mechanical (tactile)
surface stimulation/feedback. An additional factor that evokes visual feedback and
proprioception is the operation of a prosthesis. Utilizing electrical or mechanical
stimulation through six different intervention modalities, demonstrated in Figure 2.1,
diversifies the proposed treatment to better understand the positive and negative
effects of each treatment strategy. Figure 2.1, adapted from Figure 1.3 of the EPIONE
project 18-month report, shows the intervention methods and planned assessments
for determining effect.
Because of the variety of clinical implementations, the methods for sensory aug-
mentation are split among seven clinical sites. The clinical site(s) for each modality
is/are shown in Table 2.1. In order to coordinate efforts and to ensure data are
comparable among test sites, the consortium developed a CCP, which is discussed
in subsection 2.2.2. Note, the preliminary results of the EPIONE consortium are
discussed in Chapter 4, and the Indiana University - Purdue University Indianapolis
(IUPUI) clinical site case study are discussed in Chapter 5. Each of the clinical sites
achieved proper ethical approval from local authority and is registered on clinicaltri-
als.gov, as shown in Table 2.2.
2.2.2 Common Clinical Protocol (CCP)
While there are slight variations among clinical sites, such as with inclusion/exclu-
sion criteria, the consortium developed a CCP for all sites to follow. These guidelines
are mainly written with respect to experimental timeline and data collection methods
in order to avoid the problem of incomparable data, such as differing anchors in the
VAS, discussed in subsection 1.3.1. The experimental timeline in the CCP requires
7-9 weeks of intensive subject participation with an optional 8 week follow-up pe-
riod. During the baseline phase the subject is exposed to a battery of stimuli for
threshold determination, sensation characterization, and therapy parameter develop-
ment. Threshold determination is the process of ramping the intensity, pulse width,
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Methodologies
Intervention Evoked sensation
Non-invasive mechanical
pressure applied to stump
with operation of prosthesis
Touch: pressure
Proprioception
Visual
Non-invasive electrical
stimulation applied to stump
Touch: vibration
Touch: vibration
with operation of prosthesis
Invasive electrical stimulation
 applied to peripheral nerve
with operation of prosthesis
Proprioception
Visual
Proprioception
Visual
niM
niMH
niE
niEH
iE
iEH
Assessment
Daily Pre-intervention/Post-intervention
•Cortical mapping
•Psychological status and profile
•Phantom limb pain and stump pain
•Threshold and limts of sensation
•Quality, location, magnitude of sensation
•Phantom limb pain and stump pain
•Threshold and limts of sensation
•Quality, location, magnitude of sensation
•Well-being (psychological status)
Fig. 2.1. The basic design of experiment is demonstrated here. Six methodologies
elicit various evoked sensations and are analyzed for effectiveness in several
capacities. Pre-intervention and post-intervention measures (as well as daily
measures) are utilized to focus on pain intensity, pain quality, psychological profile,
and cortical mapping. The objective of the study is to develop a strategy for PLP
intervention by narrowing the focus of sensory feedback modalities and delivery
systems. niM = non-invasive mechanical, niMH = non-invasive mechanical with
prosthesis, niE = non-invasive electrical, niEH = non-invasive electrical with
prosthesis, iE = invasive electrical, iEH = invasive electrical with prosthesis.
and frequency parameters to find the sensation and discomfort thresholds for each
parameter. Doing so gives a target range for the therapist during sensation charac-
terization and therapy. Sensation characterization involves the matching of referred
sensations (RSs) to stimuli. The subject is given a stimulus, focuses on the stimulus,
and records the location and quality of the RS. Once the subject reports an RS and
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Table 2.1. Treatment delivery strategies proposed by the EPIONE consortium. The
EPIONE consortium consists of 7 clinical sites: Aalborg Hospital (AUH), Aalborg
Universitet (AAU), Centre hospitalier universitaire vaudois (CHUV), Ecole
Polytechnique Federale de Lausanne (EPFL), Lunds Universitet (ULUND), and
Universita Cattolica Del Sacro Cuore (UCSC) and IUPUI.
Invasive/ Non-invasive Clinical Test Site Intervention Method
Non-invasive
AAU, IUPUI Electrical Stimulation (niE)
EPFL Electrical Sensory Feedback
with Hand Prosthesis Oper-
ation (niEH)
ULUND Mechanical Stimulation
(niM)
ULUND Mechanical Sensory Feed-
back with Hand Prosthesis
Operation (niMH)
Invasive
AUH Electrical Stimulation (iE)
CHUV+EPFL, UCSC Electrical Sensory Feedback
with Hand Prosthesis Oper-
ation (iEH)
characterizes it, the description is paired with the stimulus parameters and stored for
therapy sessions.
2.2.3 Inclusion/Exclusion Criteria and Study Population
The inclusion/exclusion criteria are designed to limit the variability in data due
to external noise-factors. Various alterations to these criteria were made to accom-
modate the local requirements. For example, the upper age limit may be lowered
or the lower age limit raised if another limit is imposed by the local authority. The
inclusion/exclusion criteria according to the CCP appear in Table 2.3.
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Table 2.2. The clinical sites for the EPIONE consortium are all registered on
clinicaltrials.gov.
Clinical ClinicalTrials.gov Study Name
Site Identifier
AAU NCT02488668 Surface Electrical Stimulation for Treatment
of Phantom Limb Pain (EPIONE)
AUH NCT02493842 Direct Nerve Stimulation for Treatment of
Phantom Limb Pain (EPIONE)
CHUV+EPFL NCT02569918 Use of Hand Prosthesis With Surface Elec-
trical Stimulation for Treatment of Phantom
Limb Pain (EPIONE)
CHUV+EPFL NCT02796495 Use of Hand Prosthesis With Direct Nerve
Stimulation for Treatment of Phantom Limb
Pain (EPIONE)
IUPUI NCT02519907 Surface Electrical Stimulation for Treatment
of Phantom Limb Pain (EPIONE)
UCSC NCT02506608 Use of Hand Prosthesis With Direct Nerve
Stimulation for Treatment of Phantom Limb
Pain (EPIONE)
ULUND NCT02589080 Phantom Limb Pain: Efficacy of Non-
invasive Sensory Feedback Through the Pros-
thesis (EPIONE)
2.2.4 Experimental Timeline
The experimental timeline spans 17 weeks and is divided into 6 phases, which
are pre-screen (1 week), baseline (2 weeks), entry (1 week), intervention/therapy (4
weeks), outcome (1 week) and follow-up (8 weeks, optional). The first week, pre-
screen, of the trial timeline is used to determine whether or not the potential subject
meets the site-specific inclusion and exclusion criteria (described in subsection 2.2.3).
The pre-screen, baseline, and entry visits make up the pre-therapy period, where
data is collected to serve as points of reference for data collected throughout the
therapy phase and during the outcome phase. After the pre-screen phase, the study
subjects establish baseline measures for self-report questionnaires and attend sessions
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Table 2.3. Inclusion/Exclusion criteria
Inclusion/ Criteria
Exclusion
Inclusion
• Adult man or woman > 18 years and < 70 years.
• Unilateral transradial amputation or unilateral lower extremity
amputation.
• Other treatments for PLP tried with poor results. Patient ac-
cepts the study protocol as explained by the physician.
• The subject must experience intractable PLP more than 6 on
Numeric Rating Scale (NRS) or VAS (0-10 scale). The frequency
of PLP attacks must present itself more than once a week.
• Amputation should be in the chronic, stable phase, such that the
stump has healed and the person apart from phantom pain, is
healthy and able to carry out the experiment.
Exclusion
• Cognitive impairment
• Current or prior psychological impairments: Major personality
disturbance (i.e. borderline, antisocial), Major depression, Bipo-
lar I
• Pregnancy
• History of or active substance abuse disorder
• Acquired brain injury with residual impairment
• Intellectual Disability (IQ < 70)
• Prior neurological or musculoskeletal disease
• Current or prior dermatological conditions
• Excessive sensitivity to electrical stimulation with surface elec-
trode. People afraid of electrical stimulation or pain.
• Persons with other diseases that may affect the function of the
nervous system (Diabetes, HIV, Renal Failure)
• Persons with pacemakers
to identify and locate areas of RS on the residual limb. Prior to initiating the therapy
phase, the subject undergoes a functional magnetic resonance imaging (fMRI) session
to establish baseline functional maps for given tasks. The therapy phase lasts 4 weeks
and requires the subject to attend 3-5 sessions per week, in which he/she completes
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psychophysical questionnaires according to Table 2.4. Following the therapy phase,
a second fMRI along with a barrage of self-report questionnaires are completed in
the outcome phase to compare to the pre-therapy data. Some of the instruments are
clinical site specific.
Table 2.4. Outline of experimental instruments and their use in the experimental
timeline (P=Pre-Screen, B=Baseline, E=Entry, TX=Therapy, O=Outcome,
F=Follow-up) [166]. X indicates administration of the instrument. D indicates
administration of the instrument (at each scheduled session) in the given phase.
*indicates the primary instrument for assessment of efficacy. **indicates the
secondary instruments for assessment of efficacy.
Type Abbr Test Name
Clinical Assessment (CCA)
P B E TX O F
Mental Status
PHQ-9 Patient Health Questionnaire X X X X
POMS-SF** Profile of Mood States X X X X
WASI Weschler Abbreviated Scale of Intelligence X
Phantom Pain
NPSI** Neuropathic Pain Symptom Inventory X X X X
VAS* Visual Analog Scale X D D D X D
BPI Brief Pain Inventory X X X
PsyP-Map Psychophysical Map of Sensation X D X D
PGIC Patient Global Impression of Change X
Cortical Map
SEP Somatosensory Evoked Potential X X
fMRI functional Magnetic Resonance Imaging X X
TMS Transcranial Magnetic Stimulation X X
2.3 Data Collection
As demonstrated in Table 2.4, the VAS serves as the primary instrument for mea-
suring effect, while the NPSI, and POMS-SF serve as secondary measures. The VAS,
NPSI, and POMS-SF fall under the umbrella of self-report questionnaires. These self-
report questionnaires are chosen to represent the preliminary data shown in Chapter
4 because they span the primary experiential dimensions of pain [25]. The VAS serves
as a measure of pain intensity, the POMS-SF reflects pain affect, and the NPSI mea-
sures pain quality. Several other instruments are incorporated in the clinical study,
as shown in Table 2.4; however, all besides the VAS, NPSI, and POMS-SF are out
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of scope for this review of preliminary, pilot data and will be covered in subsequent
reports on a center-by-center basis. Chapter 5 discusses these exploratory data in
more depth for the case study at IUPUI.
2.3.1 Pain Intensity
The VAS is utilized in several capacities to characterize the effects of therapy.
First, it is utilized to determine the immediate effects of therapy, inquiring about
present pain intensity and average pain over the last hour. Secondly, the VAS informs
of changes to pain intensity on a daily basis by asking about average pain over the last
24 hours. These measures are collected before and after pre-therapy visit, as well as
before and after each therapy session, allowing comparison of therapy scores to those
collected in the pre-therapy period. The VAS is presented as an integer-enumerated,
continuous line spanning 0-10 with the 0-anchor being “No pain” and the 10-anchor
being “Worst pain imaginable”.
2.3.2 Pain Affect
The POMS-SF, as described by Baker et al., reflects a subject’s present state of
mood [167]. The POMS-SF uses 37 questions on 5-point NRSs (from 1=“Not at all” to
5=“Extremely”) to describe the subject’s mood, which gets summarized 6 categories.
In the pilot study the POMS-SF was utilized weekly, but the frequency was increased
to every visit to better understand effects of therapy after the preliminary results
were collected.
2.3.3 Pain Quality
The NPSI, presented by Bouhassira et al., measures the qualities of neuropathic
pain (NP), in terms of six subscores [99]. The individual completing the questionnaire
answers 12 questions, 10 of which are utilized in the pain quality assessment. The
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other two questions refer to the timing and frequency of pain. The NPSI uses NRSs
spanning 0 − 10 with the 0-anchor being “None” and the 10-anchor being “worst
imaginable” in the context of each question. In the preliminary pilot study, Chapter
4, the NPSI was seldom used (once per week during therapy). However, the frequency
was increased to every visit in later rounds of testing.
2.4 Methods for Assessment
Methods for analyzing data in single case research (SCR) vary widely in literature.
While it is important to conduct randomized controlled trials (RCTs) to determine
an effect with confidence, pilot studies often rely on small sample sets to determine
whether or not to continue to conduct a larger trial. There are several methods to
analyze single case data [168]. Rather than relying on a diverse sample set, the meth-
ods for SCR require a higher sample size per subject to establish reasonable power.
Unlike Cohen’s d, which assumes normal distributions [169], the nonoverlap of all
pairs (NAP) method proposed by Parker and Vannest does not assume a distribution
shape [170]. In justifying the necessity of a new method for analyzing effect in SCR,
Parker and Vannest specify two advantages of NAP over parametric methods: (a)
SCR commonly fail to meet the parametric assumptions of independence, normality,
homoscedasticity and (b) NAP does not rely on equal variance and normality. While
NAP allows interpretation of results for which typical parametric methods cannot,
one should not discount the value of properly powered experiments. Like other meth-
ods for SCR the NAP is a crude metric that can be used in determining treatment
validity at a pilot study level.
The following subsections discuss the methods used to analyze data from each of
the instruments included in the EEP. These are categorized according to the aspect
of pain to which they relate, e.g. the VAS relates to pain intensity. There are two
basic methods for establishing effect for these data. The NAP method is used for the
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VAS scores, while the BPI interference scale (BPI-IS), NPSI, and POMS short form
(POMS-SF) subscores all rely on variations of Cohen’s d for effect size.
2.4.1 Pain Intensity
The scores from the VAS are analyzed using the NAP method [170]. This is
possible because of the brevity of the questionnaire. In order to use the NAP method,
data is separated into bins, one pre-therapy bin, combining the scores from pre-screen,
baseline, and entry, and one bin for each week of therapy. Note, these terms are
further defined in Chapter 2, where the common clinical protocol is discussed. The
scores from each therapy bin (t-scores) are then compared individually to each pre-
therapy score (p-scores), creating an Np×Nt comparison matrix. If a t-score is lower
than a p-score (i.e. pain intensity drops during therapy) the comparison receives a
value of 1, if the t-score and p-score are equal the comparison receives a value of
0.5 and if the t-score is greater than the p-score, the comparison receives a value
of 0. To calculate the NAP score, these comparisons are averaged together. As an
example if the scores improve, the expected NAP is between 0.5 and 1.0. Typically,
this measure spans 0.5 − 1.0, where 0.5 represents a chance-level result [170]. Some
have reported the measure spanning 0 − 1 using a linear transformation, where 0 is
the chance-level result [168]. However, because of the possibility of negative results
(especially in immediate measures of pain after surface stimulation), in the present
work the measure is expanded from the typical range of 0.5 − 1 to 0 − 1 where 0.5
still represents a chance-level result. As suggested by Parker and Vannest scores from
0−0.49 represent deteriorating performance [170]. Using the limits for positive effect
established by Parker and Vannest [170] and reflecting the limits over the midline to
create limits for negative effect, the following guidelines in Table 2.5 for effect were
created. The NAP analysis method and the limits in Table 2.5 are used for all three
of the VAS measures described above.
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In addition to the NAP, it is beneficial to look at general trends of the VAS,
especially referring to the pre-therapy pain intensity. Thresholds for mild, moderate,
and severe pain are adapted from recommendations by Jensen et al., who suggested
0= no pain, 1-4= mild pain, 5-6= moderate pain, and 7-10= severe pain [98].
Table 2.5. Using the NAP method (ranging 0− 1 and centered at 0.5 as
chance-level) for analyzing VAS scores allows interpretation of positive and negative
results. NAP limits can be calculated from Cohen’s d using the equation provided
by Parker and Vannest [170]; however, they suggest broadening the limits for effect
for SCR.
NAP Limits Adjusted
from Cohen’s d NAP Limits Effect
0 − 0.30 0 − 0.07 Large/Strong Negative
0.31− 0.37 0.08− 0.33 Medium/Moderate Negative
0.38− 0.62 0.34− 0.66 None
0.63− 0.69 0.67− 0.92 Medium/Moderate Positive
0.70− 1 0.93− 1 Large/Strong Positive
As described later, depending on the distribution of the pain in the NAP analysis,
two datasets with the same averages for p-scores and t-scores could give very different
results. While this is normally an expectation, i.e. tighter distributions have more
power, only analyzing the NAP scores without referring back to the VAS scores and
trends does not paint the full picture. This is especially true for PLP since pain often
comes in flares.
2.4.2 Pain Affect
POMS-SF
The POMS-SF subscales are analyzed by comparing differences in average p-scores
and average t-scores from each therapy week. Effect size is determined using the stan-
dard deviation (SD) of a larger population [167]. According to Cohen’s conventional
50
framework, a large effect is reflected by a difference in mean scores that is 80% of
the SD, and a medium effect requires a difference in mean scores that is 50% of the
SD [169]. Ideally, the SD used for calculating Cohen’s d would come from a large
population of individuals in a similar stage of life, demographic, and etiology to the
sample population of interest. In this case the non-depressed population is used from
Baker et al. as a reference sample [167]. This is appropriate for the pilot study;
however, when expanding to a larger RCT, a better representative reference sample
could improve the impact of the results. The Cohen’s d for each week is calculated
according to the following equation,
d =
µt − µp
σ
(2.1)
where µt represents the mean score in a therapy week, µp represents the mean score
in the pre-therapy period, and σ represents the SD of the reference population. In
order to generate thresholds for effect, Equation 2.1 was algebraically solved for the
required change in average score to achieve a strong or medium effect, as in Equation
2.2.
µt − µp = ∆µ = d · σ (2.2)
The POMS-SF vigor score is positive facing, i.e. an increase in the mean score from
pre-therapy to therapy (positive d) indicates a positive result, following Equation 2.2.
Conversely, the other five POMS-SF subscales are negative facing, i.e. an increase in
the mean score from pre-therapy to therapy is a negative effect. For negative facing
scores a positive d is a negative change (or drop) in the score. These subscales have
the opposite conditions of that in Equation 2.2 and require changing the direction of
the calculation in Equation 2.2 by simply multiplying by −1, as in Equation 2.3,
− (µtneg − µpneg) = −∆µneg = d · σ (2.3)
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where µneg represents the mean of a negative facing subscale, as defined above. Table
2.6 shows the limits for effect interpreted from Baker et al. [167] using Equation 2.2.
These values represent changes in the subscale, or ∆µ in Equation 2.2.
Table 2.6. The limits for effect are adapted from the SDs in the sample population
of a study by Baker et al. [167]. Cohen’s d is considered to be bidirectional, allowing
the interpretation of both positive and negative effects.
POMS-SF Subscale Strong Negative Medium Negative Medium Positive Strong Positive
Subscale Range Effect (d = −0.8) Effect (d = −0.5) Effect (d = 0.5) Effect (d = 0.8)
Anger 7− 35
Confusion 5− 25
Depression 8− 40 3 2 −2 −3
Fatigue 5− 25
Tension 6− 30
Vigor 6− 30 −4 −2 2 4
Even though the effect-thresholds are the same for each of the negative facing scores,
the possible range for a given score varies because of the method of subscale calculation
described by Baker et al. [167].
BPI-IS
While the BPI-IS is not one of the primary or secondary instruments, it is discussed
in detail in Chapter 2 using the following methods. After collection of the BPI-IS, a
final score is calculated from the responses by averaging the responses to the seven
interference questions, arriving at a “total interference”; as with the others this ranges
from 0 (“Does not interfere”) to 10 (“Completely interferes”). Using SDs from a
reference population, the effect-thresholds for the difference of p-scores and t-scores
are demonstrated in Table 2.7. Analysis involves the comparison of all individual
subscales for this exploratory measure. Note, in this instrument the thresholds include
2 significant figures. This is different from the other instruments. The purpose is that
if the subscales were rounded to the nearest integer, some subscales (e.g. Mood) would
have the same thresholds for both moderate and strong effect.
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Table 2.7. The limits for effect in the BPI-IS are adapted from the SDs in the
reference population [112]. Cohen’s d is considered to be bidirectional, allowing the
interpretation of both positive and negative effects. All subscales range 0− 10.
BPI-IS Large Negative Medium Negative Medium Positive Large Positive
Subscale Effect (d = −0.8) Effect (d = −0.5) Effect (d = 0.5) Effect (d = 0.8)
General Activity 2.4 1.5 −1.5 −2.4
Mood 2.4 1.5 −1.5 −2.4
Mobility 2.5 1.5 −1.5 −2.5
Normal Work 2.5 1.5 −1.5 −2.5
Relationships 2.4 1.5 −1.5 −2.4
Sleep 2.7 1.7 −1.7 −2.7
Enjoyment of life 2.8 1.8 −1.8 −2.8
Total 2.1 1.3 −1.3 −2.1
2.4.3 Pain Quality
Pain quality, measured with the NPSI, is analyzed in a similar fashion to the
POMS-SF and BPI-IS. SDs taken from a reference population [171] are utilized to
compare the means for t-scores and p-scores as in Equation 2.1. The NPSI subscales
are all negative-facing requiring the transformation in Equation 2.3. In this case SDs
from the reference population were broken up into four subgroups according to the
reference study protocol [171]. Because the SDs for the four subgroups were reported
separately and varied slightly, the maximum baseline SD of the four subgroups was
used as the reference SD for each subscale. Table 2.8 demonstrates the effect-threshold
or the required delta for each NPSI subscale.
2.4.4 Group Analysis
In order to analyze the group data, the same thresholds are used as described in
the previous subsections. Equation 2.4 demonstrates how the weekly average scores
are calculated for each subscore,
y¯i. =
1
n
n∑
j=1
yij (2.4)
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Table 2.8. SDs from Table 1: NPSI scores at baseline, provided by Bouhassira et
al. [171], allow the interpretation of positive and negative effects with respect to
pain quality. All subscales of the NPSI are negative facing, meaning that the desired
(positive) effect is a drop in magnitude. Recall that all NPSI subscales range from
0-10 except the NPSI - Total subscale, which ranges 0-100.
NPSI Subscale Strong Negative Medium Negative Medium Positive Strong Positive
Subscale Range Effect (d = −0.8) Effect (d = −0.5) Effect (d = 0.5) Effect (d = 0.8)
Burning
Pressing
Paroxysmal 0− 10 2 1 −1 −2
Evoked
Paresthesia/
dysesthesia
Total 0− 100 16 10 −10 −16
where i denotes the therapy week, j denotes the subject index for the group, n is
the total number of subjects, yij is the averaged subscore for a subject, and y¯i. is
the group average for a given subscore. An overall average calculated according to
Equation 2.5,
y¯.. =
1
an
a∑
i=1
n∑
j=1
yij (2.5)
where a denotes total number of time periods for analysis and y¯.. represents the
overall average across subjects and time periods for a subscore. Calculating the
sample standard deviation across subjects utilizes the results of Equation 2.4 and
Equation 2.5 as in Equation 2.6,
Si =
√√√√ 1
n− 1
n∑
j=1
(y¯.j − y¯..)2 (2.6)
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where Si represents the sample standard deviation across subjects for a subscore
and is calculated for each time period. Calculating the group difference scores for
comparison against thresholds in Table 2.8, for example, is done with Equation 2.7,
D¯i =
1
n
n∑
i=1
(y¯i. − y¯1.) (2.7)
where D¯i is the average difference score for a psychophysical subscore and y¯1. is the
pre-therapy score.
Handling Problematic Data
In the current paradigm the difference scores are directly used to identify the
effectiveness of therapy, and if data is collected according to the protocol, Equation
2.7 can be used. However, if data is missing Equation 2.7 breaks down and more
sophisticated tools are needed. An important question to consider is how to handle
missing data. Little et al. describe the likelihood of such occurrences as well as a few
procedures for data handling [172]. A popular technique is imputation by the last
observation carried forward, which simply means inserting the immediately previous
data point into the empty position. Alternatively, data models can be created to
estimate the missing data points, or a subject with missing data can be removed
from the subject pool entirely. In any of these circumstances it is important to weigh
alternatives and choose a method based off of sensitivity analyses [172].
2.5 Conclusions
In the midst of designing, the multi-center clinical trial, it became apparent that
a substantial amount of data would be collected through the self-report question-
naires. Each questionnaire has its own flavor of data collection. For example, the
questionnaires use various NRSs and calculated subscales. The opportunity for data
analysis errors is immense when converting to an effect size. The obvious solution
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to this dilemma is automation. In order to automate the data consolidation, orga-
nization, and analysis, the EEP was conceived. For the EPIONE consortium, who
identified the need to automate analysis of the self-report data coming from the EPI-
ONE Psychophysical Platform (PsyP), the EEP is a software tool that consolidates
and analyzes PsyP data. Unlike relying on each clinical site to review questionnaires
individually and manually process results, the EEP automates analysis and reduces
opportunities for analysis error and user error. Chapter 3 introduces the EEP and
the EEP-Group Analysis Module, which takes output files from the EEP to establish
group-wide effects. With the EEP software tools, researchers are able to accurately
analyze SCR data and prepare group data for statistical analysis.
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3. DEVELOPING A SOFTWARE FOR CONSOLIDATING
SELF-REPORT DATA
3.1 Introduction
Prior to developing the software tool for data analysis, called the EPIONE Extrac-
tion Program (EEP), two business analysis models, the context diagram and process
map, were created to understand the requirements. As with any software, important
requirements were discovered and incorporated throughout development; however,
going through the practice of predicting the structure, inputs, outputs, etc. before
digging into the code, unveiled several requirements that could have severely delayed
the date of delivery. After designing the software, the EEP was subjected to several
tests to ensure the output consists of accurate, high quality results. Testing revolved
around the requirements and primarily involved testing for data accuracy and soft-
ware usability, assuring that the software meets expectations. In the end a software
was developed to analyze data from the brief pain inventory (BPI), neuropathic pain
symptom inventory (NPSI), profile of mood states (POMS) and visual analog scale
(VAS).
3.2 Design Considerations
The two chief tools used to model the system interactions are the context diagram
and process map. The context diagram is crucial to understanding who or what is
expected to provide vital information to achieve the goal, which is in this case ana-
lyzing the data. This diagram, displayed in Figure 3.1, demonstrates the interactions
of the EEP and user as well as the interactions of the EEP with the local system.
Through depicting the software in this light, it became apparent that the user must
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be familiar with the data being exported to some extent, i.e. the user must be able
to point to the data of interest. Since this method is new to all of the consortium
researchers, there is an expectation that some of the information required by the EEP
could potentially be confusing to the user. For this reason another requirement is to
provide “immediately available” help dialog to the user.
EPIONE 
Extraction
Program
Program User
Local System
(PC or Mac)
                              Path to PsyP Data
                    Path to username file
                        Study ID
     Path to W
orking/Save Directory
          Location of Study
                     D
ata of Interest (BPI / NPSI / POMS / VAS)
                     O
u
tput Form
ats of interest (-xls -mat -fig -svg)
          Visual Feedback of Entries
   Suggestions for Resolving User Inp
u
t E
rro
rs
                Feedback of Extraction Progress
      Immediately Accessible Help Text
 
        R
ead PsyP Platform
 Data Files
       W
rite Requested Output Files
                    Write Access to W
orking D
irectory
   
     
             
                      Read Access to Data D
irectory
               MATLAB Runtim
e Engine
     Error Debugging Inform
ation
                W
rite Log File
Fig. 3.1. Several interactions between the user and EEP and between the local
system and EEP helps identify several requirements that need to be incorporated
into the EEP.
Interacting with the host or local system is much simpler, but equally important.
The main requirements that came out of analyzing this interaction deal with access
permissions. Fortunately, the risk of not having permission to read or write to the var-
ious directories is low. Data from the EPIONE Psychophysical Platform (PsyP) are
typically saved to a specific folder on the windows operating system, which does not
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require special or administrator permissions to read or write. Furthermore, the users
will typically navigate to a writable directory for saving output files. Nevertheless,
these requirements are relevant to successfully generating an output. Installation of
the MATLAB R© Runtime Engine is a requirement for the EEP because of the expec-
tation of using MATLAB R© as the primary development tool. This developer platform
was chosen because the format of the PsyP output data is native to MATLAB R©.
The process map (Figure 3.2) reveals the underlying structure devised for the
EEP. This is where the design of the software begins to take form. The top row
of boxes represent the ways the user can interact with the EEP; notice how these
buttons align very closely to the information provided by the user as displayed in the
context diagram (Figure 3.1). The basic flow for the user to enter information into
the EEP is: (a) the user clicks a button, informing the EEP what type of information
the user would like to enter, (b) the EEP initiates the appropriate user interface (UI),
if necessary, and (c) the user then points to or enters the information, which is saved.
Each button along the top row can operate independently and does not rely on
any particular order. While this feature of the software is convenient and less restric-
tive, it opens up an opportunity for error if the user haphazardly tries to analyze
results without entering all of the relevant information. Thus, a system requirement
is necessary to prevent the software from attempting to analyze data if input infor-
mation is missing. However, this alone is not enough. The system must also provide
feedback to the user, requesting the missing information. This requirement was a
suggestion from early beta-testing of the EEP with the partners at Aalborg; users
suggested generating some form of feedback to the user on processing progress and
upon completion of processing.
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3.2.1 Designing Software to meet Specific Requirements
The information from the two models discussed above, along with several rounds
of alpha and beta-testing of various features, led to the generation of the abbreviated
list of requirements demonstrated in Table 3.1.
Table 3.1. The requirements are each given a unique requirement identifier (RID).
The notation describes system requirements (SR) and user requirements (UR).
RID Requirement
SR1 The system shall be available on Apple and PC platforms.
SR2 The system shall provide help buttons.
SR3 The system shall be capable of outputting data in Excel R©, MATLAB R©, and
graphic formats.
SR4 The system shall have permission to read data from the user selected data
directory.
SR5 The system shall have permission to write data to the user selected working
directory.
SR6 The system shall create a log file for each run.
SR7 When an error occurs the system shall notify the user and write error in-
formation to the log file.
SR8 The system shall display a progress bar during processing.
UR1 The system shall allow the user to select a working directory.
UR2 The system shall allow the user to create an alphanumeric subject ID.
UR3 The system shall allow the user to select the username.xml file.
UR4 The system shall allow the user to select the directory containing PsyP data.
UR5 The system shall allow the user to specify the location of study as “Den-
mark” or “Other Site”.
UR6 The system shall allow the user to request any combination of the four data
types: BPI / NPSI / POMS / VAS.
UR7 If the user selects a data directory that does not contain one or more of the
requested data types, the system shall process the requested data that does
exist in the selected directory if any.
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3.3 The EPIONE Extraction Program (EEP) Input Panel
The software was created with the requirements listed above (among others) as
the principal reference for driving design decisions using MATLAB R© R2016a with
the application compiler toolbox. The requirements deal primarily with the UI of the
software and not analysis of the resulting output. Comparing the EEP input panel
(Figure 3.3) to the context diagram and process map, the layout of the input panel
closely matches the models. Results analysis makes up an aspect that is both included
and separated from the EEP. As discussed in the following section, the methods of
analysis are slightly different for each instrument. For initial analysis of the self-report
data, the first goal of the EEP is to consolidate and present the single case research
(SCR) data in a format that is accessible to the researcher/user. For analysis of the
self-report instruments, the user must compare the results to the thresholds of effect
size, which are discussed in section 2.4.
Fig. 3.3. The Layout of the of the EEP follows the basic flow of the process map.
Many of the design considerations are a direct result of the preconceived
requirements identified during modelling.
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3.3.1 EEP Results File
Stakeholders requested the output of the EEP to be in a format for comparing
results directly to the previously mentioned thresholds. In addition a researcher/user
should be able to follow how the calculations of results were performed. Some final
requirements of the software consider these details, where the effect size should not
only be available after processing, but the details of the calculation should also be
available to recreate the analysis if desired. As described in subsection B.2.3, the
output file provides the raw data, intermediate calculations, and final results to fulfill
these requirements.
3.4 Software Testing
Throughout the development of the EEP, individual processes were examined. Re-
ferring back to Figure 3.2 each process stream could operate independently, ensuring
usability. However, testing the software as a system is a vital step to validation. In
the end there were two vital considerations for testing: (a) is the information accurate
and (b) is the software tool usable? The testing discussed in the remainder of this
chapter focuses on usability, which relates to providing informative help messages,
outputting results in a convenient format, and preventing foreseeable user errors.
Testing of accuracy was completed by looking at randomly selected PsyP output files
and comparing to the output of the EEP.
3.4.1 Providing Sufficient Help Documentation
An initial test of usability involved a use case where an EEP user, unfamiliar with
the project is asked to open the software and complete analysis, with the immediately
available help information. The following scenario was given to the user as background
information:
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“You have finished processing the data for your first subject in the psy-
chophysical platform (subject z01cc); this study was conducted at Indiana
University - Purdue University Indianapolis. His Study ID was ABC123.
Data needed for preliminary analysis is VAS, NPSI, and POMS. In order
to present the data to your principal investigator, you will need the figures
in addition to the Excel R© and mat-data.”
The user was not given the user guide to check if the immediately available help
messaging was sufficient for operation. A successful outcome for this test was de-
termined to be if the user (a) selected the correct data types and (b) completed
extraction. Analysis or interpretation of the EEP data was not included in this test.
In all three tests the users successfully navigated through each step of the EEP
input panel and achieved the successful outcome criteria. Two users were able to
achieve the successful criteria through the basic flow (i.e. following the process map as
expected). The other user achieved the successful criteria through an alternative flow
(i.e. the EEP prevented initial processing and requested the missing input information
before proceeding). In this case the user did not select the location of study. The
results of this test reveal that the software input panel is intuitive and easy to use,
even in the absence of the user guide.
3.4.2 Varying Structures of PsyP Data
Two predictable, expected ways the analysis process could be impacted are by the
data that are available to process and the data that are requested for processing. For
example, it is possible for the user to request POMS-SF, NPSI, and VAS data when
only POMS-SF and NPSI data are available in the data directory. This situation
captures both scenarios, where (a) the BPI data were not requested (b) the VAS data
were requested, but do not exist.
Because of the relevance and likelihood of this happening, a full factorial design
was implemented to test these scenarios. Five data sets were created for this test
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procedure. The first data set contains data for each of the instruments (BPI, NPSI,
POMS-SF, and VAS). The other five data sets are comprised of the same files minus
one instrument (i.e. the second data set has NPSI, POMS-SF, and VAS data, but no
BPI data). Finally, a directory was created that did not contain any of the data in
the first data set (i.e. the directory was empty). From the perspective of requesting
data, there are 64 different scenarios. This is because there are four data types and
two optional data formats (total of 6 binary user options). Therefore, with the full
factorial design, 384 separate tests are required. For the test to be successful, each
test must complete with the appropriate output files, or for the EEP to request the
user to select data for processing (if no data types are selected on the input panel).
If a data type is not present in the data directory selected by the user, the system,
according to the previously defined requirements, must process the existing data that
is selected by the user. This test ensures to the user requirements suggested previously
are met. Specifically, it addresses whether or not the system allows the user to request
any combination of the four data types (BPI / NPSI / POMS / VAS). The test also
confirms whether or not the system can process the existing data even if data that
do not exist are requested.
In each of the 384 tests, the program successfully met the requirements. This
suggests that no matter what the input data structure looks like, the EEP should be
capable of extracting any requested data that are available. This test generated 1,540
output files, so data accuracy and quality were verified by randomly selecting files
from each group and comparing back to the true values, which showed an accuracy
of 100%.
3.5 EEP-Group Analysis Module (EEP-GAM)
While the EEP provides a certain level of convenience to the user on its own,
filling the need to evaluate SCR data, an additional module is required to complete
the analysis. This is fulfilled by the EEP-Group Analysis Module (GAM). After
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analyzing several subjects using the EEP, group analysis can be done by simply
pointing to a particular output file from EEP analysis for each subject of the group.
In this way the GAM acts as an extension of the EEP because it relies on data
generated by the EEP during single subject analysis/extraction.
3.5.1 GAM Features
There are several useful, built-in features of the EEP-GAM, which is depicted in
Figure 3.4. The input panel is organized into three sections, having a menu pane,
workspace, and output pane. As demonstrated in Figure 3.4 a user can input subjects
for multiple groups, which can be of any order or size. A user has the option to process
BPI, NPSI, POMS, or VAS data and can generate outputs in three formats: Excel R©
files, mat-files, and figures. In addition, the workspace can be saved to add additional
subjects to a group later or for future reference. Instructions for using the EEP-GAM
can be found in Appendix B.
3.5.2 GAM Results Files
As with the EEP analysis, there are predictable situations to account for in regards
to analysis. Since this module is an extension and not a stand-alone program, it relies
on the consistent output format of the EEP. It is possible that a subject used in this
module is missing data for a certain time period. This is acceptable; in these situations
the GAM does not consider that particular subject in the affected measure and week,
for example a group average is calculated using every available score. An additional
scenario is if the user does not select all data types or formats to be processed. Each
of these situations should be tested to ensure the program correctly accounts for the
different situations. The data for each group can be consolidated into a single Excel R©
file and/or single mat-file if selected by the user. Each data type produces a single
figure for every subscore, as well as a figure depicting the average of all subscores,
e.g. if the “BPI” data type and the “Figures” output format are selected 18 figures
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Fig. 3.4. The user interface of the EEP-GAM is intuitive and easy-to-use.
would be generated for each group, nine figures with the MATLAB R© FIG extension
and nine figures with the scalable vector graphics (SVG) extension. Both NPSI and
POMS produce 14 figures and VAS produces 16 figures, addressing the VAS and NAP
scores. If all data types and formats are selected, 33 FIG and 33 SVG files are created.
The number of output files when analyzing two groups at one time totals up to 136
files if all data types and output formats are selected.
3.5.3 GAM Software Testing
Testing the software involves 128 cases for every combination of data type and
output format selections. The subject table, demonstrated in Figure 3.4, has two
groups and is an interesting use case for testing. In this situation there are two
groups of unequal size and the subjects are assigned to the groups out of order. All
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in all, the testing of 128 cases produced 7,184 output files. The randomly selected
output files were compared to manually calculated results showing 100% accuracy. In
the cases where no data types were selected or no data output formats were selected,
the GAM prompted the user to make selections.
3.6 Conclusion
With the newly designed EEP and EEP-GAM, analysis of the self-report data
should be exceptionally faster and more reliable than the alternative option of man-
ual extraction and processing. Instead of hours to days, the EEP only takes up to 30
seconds to generate the output files and the EEP-GAM takes 2-3 minutes. Further-
more, the EEP and EEP-GAM reduce the opportunity for errors in manual process-
ing. Developing requirements prior to beginning the development of the code likely
prevented several project delaying road blocks. From the usability testing described
above, the EEP seems to be a convenient, easy to use tool to add to the software
developed during the EPIONE project. The self-report data shown in Chapter 4 and
Chapter 5 were extracted using the EEP. This provided an opportunity to test the
performance and robustness of the EEP with data of various structures and with data
from several clinical sites.
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4. A PILOT STUDY TO INVESTIGATE THE EFFECTS
OF COGNITIVELY REINFORCED STIMULATION ON
PHANTOM LIMB PAIN
4.1 Introduction
With the prevalence of amputation expected to double over the next few decades,
mainly due to dysvascular conditions, the sequelae associated with amputation be-
come more and more relevant [4]. Numerous treatment methodologies, including
pharmacological, non-pharmacological and surgical, for phantom limb pain (PLP)
have been proposed, but none have clearly demonstrated success in alleviating PLP
[109,122,123]. This is further supported by lack of a standard of care for PLP [126].
The EPIONE consortium designed and implemented a multi-center clinical trial to
test the effectiveness of a new therapy paradigm for PLP [166]. Using electrical stim-
ulation coupled with operant conditioning, the consortium seeks to determine the
feasibility of this mechanism-based approach for treating PLP. We are attempting to
restore post-amputation central nervous system (CNS) changes through appropriate,
meaningful sensations and natural sensory feedback to the phantom hand or tran-
sected nerves. Through this process we expect to control PLP and better understand
the psychological, cognitive, and neuroplastic components in modulation of PLP. In
trials with small sample sizes, paradigms involving electrical stimulation have demon-
strated neuroplastic changes in the cortex [148]; similarly, elements of Graded Motor
Imagery (GMI) [173], such as mental imagery and mirror therapy, have also shown
success [146,157]. Prior research in the field suggests a potential successful treatment
may require the incorporation of sensory feedback with cognitive reinforcement [174].
Herein, several variants of this paradigm are proposed emphasizing the sensory feed-
back and operant conditioning guiding principles. In order to properly assess the
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success of these modalities and to identify the effects of therapy, we utilize self-report
questionnaires and functional imaging in the study design. Yoshida et al. provide a
high-level overview of the EPIONE consortium’s study design [166]; this chapter takes
a deeper look at the methods involved in collecting data as well as some preliminary
consortium-wide results of selected instruments.
4.2 Results
Results are organized according to the dimension of pain being measured. The
VAS scores measure pain intensity. The POMS-SF measures pain affect and NPSI
demonstrates changes to pain quality; both do so by observing changes from therapy
to pre-therapy. Three niE subjects, one niEH subject, 1 niMH subject and 1 iE
subject make up the group of preliminary data. The scores were averaged to create
a seventh set of data, shown as “Group” in the figures below. These data represent
the average effects of therapy for the preliminary dataset. Error bars on figures
represent the maximum and minimum value reported for a particular subject. For
the Group dataset, the maximum and minimum values reflect the absolute maximum
and absolute minimum reported. The results of each subject in the following sections
were extracted using the the EPIONE Extraction Program (EEP).
4.2.1 Pain Intensity: VAS Results
The primary measure of effect, average pain over 24 hours (Figure 4.1), shows
an improving trend over four weeks of therapy. Five of the six subjects (83%) have
pain trending downward from pre-therapy through the therapy phase. As depicted in
Figure 4.1, one subject (who started the study experiencing only mild pain) stayed in
the mild pain category. The third niE subject did not complete questionnaires in the
third week of therapy, which is why no pain is reported. On average, pain decreased
by 2 points on the VAS from pre-therapy to week-4 of therapy.
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Fig. 4.1. VAS scores spanning pre-therapy through week-4 of therapy. Five of six
show downward trend in pain intensity. On average pain intensity drops from
moderate to mild. Error bars represent maximum and minimum.
Figure 4.2 demonstrates the level of effect of therapy for each subject. The low
level of pain shown by the first subject in Figure 4.1 explains why the subject showed
little to no effect on the nonoverlap of all pairs (NAP) results, as there was little room
for improvement. In this case a positive outcome is that the therapy did not increase
pain (which is supported by the NAP of 0.5-0.55 in Figure 4.2). Two subjects had
strong improvements, three subjects had moderate improvements and two subjects
had no improvement after 4 weeks of therapy according to the thresholds set forth by
Parker and Vannest [170].
A result of particular interest is that of the subject receiving the niMH therapy.
For this subject the average 24-Hour VAS dropped by 3.2 points comparing week-4 of
therapy to the pre-therapy set (Figure 4.1). Comparing these data to that of the third
niE subject (whose VAS scores dropped from pre-therapy to week-4 by 3.4 points),
one might expect the level of effect to be similar. However, the NAP scores for this
subject remained in the moderate, positive effect range with a score of 0.80 (Figure
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Fig. 4.2. The NAP method of analysis demonstrates therapy has moderate, positive
effects on average for the operant coupled stimulation therapy paradigm. Error bars
represent maximum and minimum.
4.2), while the third niE subject rose above the strong, positive effect threshold at
0.95. The explanation of these results lie in the distributions of the reported VAS
scores. For example, if the pre-therapy scores fall only on both extremes, then the
effect might not be as impactful as if the distribution were tight. If a subject had
reported 5.2 for every pre-therapy score (the same average VAS as reported), the
effect after completing the NAP method would be strong and positive at NAP = 1.
Similarly, in the first niE subject, while the VAS scores stay in the mild range, the
NAP scores approach the strong, negative threshold for effect. These circumstances
bring to light the importance of observing both the VAS scores and the NAP scores
when looking at effect.
In addition to the average pain over 24 hours, the alternative pain intensity mea-
sures of present pain and average pain over the last hour show no effect - moderate,
positive effect for the group (shown in Figure 4.3). Both of these measures were
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expected to stay near 0.5 on the NAP scale, and represent the immediate effects of
stimulation. These measures act as indicators of whether or not the therapy sessions
trigger or cause pain. If so, the NAP scores would dip into the negative effect regions,
which occurred for some subjects. The spread of effects of therapy is quite broad, but
remains fairly consistent week to week, within each set of scores.
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Fig. 4.3. Average pain over 24 hours and average pain over 1 hour show therapy has
a moderate, positive effect. Present pain (0-Hour Measure) remains in the
None/Weak region as expected. Error bars represent maximum and minimum.
The VAS results, shown in Figure 4.1, Figure 4.2, and Figure 4.3, show trends of
improvement in 5 subjects (86%), both in average VAS score over 24 hours (Figure
4.1), and in NAP of the 24-Hour VAS (Figure 4.2). While the therapy negatively
affected some subjects in the immediate pain scores, the general trend of the imme-
diate effect of therapy is no effect - moderate, positive effect. The average 24-Hour
VAS and VAS - NAP of the 24-Hour VAS appear to be sensitive to therapy and
appropriate for measuring pain intensity. These moderate, positive of the pilot group
results support the treatment modalities
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4.2.2 Pain Affect: POMS-SF Results
Measuring pain affect can be done by reviewing the change in subscales over the
therapy phase compared to the pre-therapy period. Figure 4.4 depicts the average
POMS-SF scores reported from the pilot study group. Recall that each measure
has a different spectrum, with different maximum and minimum possible scores. The
minimum possible scores are shown within Figure 4.4; the ranges are also presented in
Table 2.6. On average the group did not exhibit negative pain affect; scores remained
at the bottom of the spectrum, which is a positive even though an improvement is
not seen. Conversely, study participants began in the middle of the vigor spectrum,
allowing observation of either positive or negative effects through the therapy phase.
For the vigor subscale in week-2 and week-3 of therapy, the group shows strong
and moderate, negative effects of therapy, respectively. In week-4 of therapy, the
group average climbs back into the none-weak effect region. Despite the moderate
correlation of vigor with both fatigue and depression seen by Baker et al. [167], the
vigor score appears to be the only measure sensitive to therapy. This result calls for
more investigation, leading to Figure 4.5.
The vigor score appears to be sensitive to therapy. Figure 4.5 depicts the average
vigor scores for each subject along with the group average. Three subjects demon-
strate negative effects of therapy, one subject shows no effect, one subject exhibits
positive effects after four weeks of therapy, and one subject failed to complete the
weekly questionnaires in the therapy phase (niMH). The subjects who exhibited pos-
itive effects in the VAS - NAP scores (depicted in Figure 4.2) are also the individuals
showing effect (positive and negative) in the vigor subscale. For three of the four
subjects showing effect in both instruments, the correlate is counter to expectation,
reduction of pain (positive effect) corresponding with depreciating vigor (negative
effect).
While some have suggested the inverse correlation of mood and pain [75], the
POMS-SF does not appear to be sensitive to this correlation. Of the subjects sampled,
74
Depression Anger Tension Confusion Fatigue
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Ef
fe
ct
 o
f M
oo
d 
(P
OM
S)
POMS - Group Averages
Pre-Tx
Tx-Wk1
Tx-Wk2
Tx-Wk3
Tx-Wk4
Min Possible
Vigor
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
#! #
Fig. 4.4. The POMS-SF questionnaire, in general, is not sensitive to the pain affect
associated with PLP. All of the negative facing scores were near the minimum
possible score, on average, meaning it is not possible to observe a positive effect of
therapy with this instrument (except in the vigor subscale). # indicates a
moderate, negative effect and #! indicates a strong, negative effect.
all reported scores at the bottom of the possible range for the negative facing scores
leaving no room for improvement. In order to better assess the effects of therapy,
alternative instruments may be required. On the other hand, the vigor subscale
demonstrated a negative effect of therapy on average. This result is of particular
interest because it is counter to the expected result considering the effects seen in
measuring pain intensity. There are several potential factors separate from PLP that
could play into drop in vigor. For example, the rigor of the intensive therapy regimen
could have taken a toll on the subjects’ liveliness. The affective aspect of pain shows
no change in a majority of the subscores. However, with respect to vigor, the pilot
group show negative results in the second and third week of therapy.
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Fig. 4.5. The response to therapy in the POMS-SF vigor subscale are negative on
average. On an individual subject-level results are mixed. One subject exhibits
moderate, positive effects after four weeks of therapy, while two others exhibit
strong, negative effects, and one shows moderate, negative results. * indicates a
moderate, positive effect. # indicates a moderate, negative effect and #! indicates a
strong, negative effect.
4.2.3 Pain Quality: NPSI Results
The measure of pain quality focuses on NP. While NPSI measures the intensity
of a given descriptor, it also breaks out the pain into several categories allowing the
observation of effect on several qualities of pain presentation. Five descriptors and
one total score (all NPSI subscales) characterize the effect of therapy. On average
effects are minimal with only moderate, positive results appearing in two subscales
intermittently, depicted in Figure 4.6. Moderate, positive effect of therapy appeared
in week-1 and week-3 of therapy for the paresthesia/dysesthesia subscale and week-3
of the paroxysmal subscale. Distributions of scores in each subscale are quite broad
(ranging 0-10 in some cases). A deeper look at the total subscale provides an overview
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of the effect of therapy on a per subject basis, since this score is itself a weighted
average of the other subscales.
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Fig. 4.6. NP symptoms throughout the therapy phase measured with the NPSI do
not significantly change on average. Two subscales show moderate, positive effects
intermittently. * indicates a moderate, positive effect.
Figure 4.7 illustrates the NPSI - Total subscale for each subject. While the group
does not demonstrate an effect, the two subjects exhibiting the highest average total
NP in the pre-therapy phase, show strong, positive effects. This data demonstrates
a major limitation of the study, subject non-compliance. The third subject shows
moderate and strong, positive effects in week-1 and week-2 of therapy, respectively.
However, after not attending therapy sessions in the third week of the therapy phase,
the total score rose in week-4. Unfortunately, it is impossible to say whether or not
the change in effect is due to missing week-3 of therapy, but it is a notable potential
factor.
One subject did not exhibit NP symptoms. As with the POMS-SF, when a subject
reports scores at the bottom of the spectrum (as with subject 1), significant improve-
ment is not possible, making the instrument negligible. In this case two possibilities
77
niE niE niE niEH niMH iE
0
10
20
30
40
50
60
70
80
90
100
NPSI Subscore - Total
Pre-Therapy
Therapy - Wk1
Therapy - Wk2
Therapy - Wk3
Therapy - Wk4
* *!
* *!*!*!
Group 
Average
Fig. 4.7. The NPSI - Total subscale reflects the effect of therapy on NP as a whole.
Two subjects reach levels of strong, positive effect. One subject does not have
substantial NP and does not show up on this spectrum. * indicates a moderate
positive effect and *! indicates a strong, positive effect.
are presented for analysis. First, the subset could be removed from the rest of the
dataset. Second, the subset could be analyzed with alternative criteria, following
that of non-inferiority. This is done by comparing the scores on the total subscale for
subject 1 in each therapy week to the pre-therapy scores where positive results also
include those which stay the same, i.e. the therapy is non-inferior to scores in the
pre-therapy phase. Results for pain quality demonstrate moderate, positive results
in a few NPSI subscores; however, the NPSI total score does not show changes over
the therapy phase.
4.3 Discussion
The primary measures, VAS and NAP, show the therapy has promise. On average
there is a moderate, positive effect of therapy in the first week that continues and
increases through the therapy phase. A positive effect was found in three of the
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four therapy methods presented (niE, niEH, and iE). In several subjects a moderate,
positive effect is seen in the first week of therapy, which is unexpected. Without
running a randomized controlled trial (RCT), placebo-effect cannot be ruled out. A
major limitation in this analysis is number of comparisons used in the NAP analysis.
Whereas, Parker and Vannest suggest a minimum of 169 comparisons of baseline to
treatment scores, (13 × 13). Most data reported here were below 100 comparisons
[170].
Most of the POMS-SF scores fall at the bottom of the spectrum, making it difficult
to see any effects. The correlation of improved pain and improved depression is an
expected result in the present data because of the association recognized in amputees
[18]. As discussed in Chapter 5 (which includes results for the third niE subject),
the improvement in depression was not indicated by the POMS-SF results, while it
was by the patient health questionnaire (PHQ-9). Vigor (the positive-facing POMS-
SF measure), requires analysis which is contrary to the other 5 POMS-SF subscores.
Improvement in vigor would mean an increase from baseline. On average the vigor
score had negative effects in therapy week-2 (strong) and week-3 (moderate), but
improved back to baseline levels in week-4. Negative effects in the vigor spectrum
without the similar results in depression and fatigue is unexpected. Baker et al.
recognized a moderate inverse correlation of vigor scores with depression scores and
fatigue scores (-0.40 and -0.45, respectively), which is a positive correlation of effect
[167]. This could be due to a difference in study population, since Baker et al.
reflects the psychometric analysis of cancer patients [167], but the cause for difference
is unclear.
For NPSI the expectation is for different subjects to have different amounts of NP
in each category or subscore; some subjects may be involved in the study and never
report or have a certain type of NP. As evident from the first subject, some amputees
experience little to no NP. Because the presentation of pain is different from subject
to subject, the NPSI - Total subscale seems like a valid measure for analyzing the
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effects of therapy on pain quality. While the average result is no effect, two subjects,
subject-3 (niE) and subject-6 (iE), trend downward and exhibit strong improvement.
4.4 Conclusions
After reviewing the primary and two secondary instruments of preliminary datasets,
the therapy method shows promise. Scores in each of the three reviewed trended to-
ward improvement, some showing moderate, significant improvement. However, some
also showed negative results and require close attention in future studies. An obvious
limitation of this preliminary review of data for the pilot study is power. Limited
sample size is cause for inconclusive results. In addition to the insufficient sample
size of study participants, the amount of data collected from each subject is also
limited. Questionnaires take substantial amounts of time and concentration; over-
sampling can lead to frustration and biased results, so consideration of contact hours
is quite important. Other limitations include subject non-compliance, e.g. not show-
ing up to daily therapy sessions resulting in missing data, and reliance on self-report
questionnaires without population norms of the sample demographic, e.g. using stan-
dard deviations from cancer studies to measure effects in a study of PLP. While the
analysis is appropriate for a pilot study, improving the methods for measuring effect
are advised.
Future directions involve specifying the therapy parameters and modalities. In
the present pilot study, there are six possible modalities of applying treatment (four
examined here) involving both non-invasive and invasive varieties. Additional pilot
studies should first be conducted to rule out any modalities that appear to be obvi-
ously inferior. In order to narrow the treatment method, future research should focus
on conducting randomized controlled trials comparing rates of success among the top
performers with a sham group. A significant consideration of the present work focused
on the cognitive aspects of treatment. While several have attempted surface electrical
stimulation as a method of treating PLP [145–148] and others have attempted to train
80
to cognitively manipulate and take control of the phantom [146, 157], pairing stimu-
lation with cognitive reinforcement is relatively novel. Doing so trains the subject to
couple meaningful sensation (electrical or mechanical in this case) with the phantom,
possibly improving mood, restoring reorganization of the CNS and alleviating pain.
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5. A CASE STUDY OF COGNITIVELY REINFORCED
ELECTRICAL STIMULATION FOR THE TREATMENT
OF PHANTOM LIMB PAIN
5.1 Introduction
Chapter 4 discussed data from the entire pilot group. Here, a case study of
two subjects at the Indiana University - Purdue University Indianapolis (IUPUI)
clinical site is analyzed to demonstrate the methods, instruments, and analysis at
a more specific level. Beyond the primary and two secondary measures sampled in
Chapter 4, exploratory measures round out the analysis to form a complete dataset.
The patient health questionnaire (PHQ-9), brief pain inventory (BPI), specifically
the interference scale (BPI-IS), and psychophysical map of sensation (PsyP-Map)
provide additional information to the affect and quality aspects of pain and phantom
sensation. The patient global impression of change (PGIC) supplies the subject’s
perception. These data in addition to those collected through the profile of mood
states - short form (POMS-SF), neuropathic pain symptom inventory (NPSI), and
visual analog scale (VAS), introduced and discussed in Chapter 2, provide insight into
the effectiveness of therapy. This study is approved through local authority under IRB
number 1409138829, and is registered on clinicaltrials.gov (identifier: NCT02519907).
5.2 Methods
The methods involved in this case study follow the common clinical protocol (CCP;
discussed in subsection 2.2.2), with three exceptions to the inclusion/exclusion cri-
teria. First, the subject pool is widened to include unilateral upper and unilateral
lower extremity amputees, including transradial, transhumoral, transtibial, and trans-
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femoral amputations. Second, the age range is extended from 18− 70 out to 18− 75.
Lastly, diabetes is removed from the list of exclusion criteria, i.e. a potential subject
with diabetes is still eligible assuming the other inclusion/exclusion criteria are met.
The reason for these changes is justified by population demographics and the etiol-
ogy of amputation. Nearly 65% of all amputees are lower extremity, and 38% of all
amputees are diabetic [4]; excluding these individuals severely limits the ability to
recruit candidates.
Following the experimental timeline outlined in subsection 2.2.4, the frequency of
measurement was slightly adjusted from the CCP. These adjustments follow Table
5.1, where the frequency of several instruments are heightened from once per week to
every session/daily.
Table 5.1. Outline of experimental instruments and their utilization in the
experimental timeline (P=Pre-Screen, B=Baseline, E=Entry, TX=Therapy,
O=Outcome, F=Follow-up). This is adapted from Table 2.4. * indicates the
primary instrument for assessment of efficacy. ** indicates the secondary
instruments for assessment of efficacy. X indicates administration of the instrument.
D indicates administration of the instrument (at each scheduled session) in the
given phase
Type Abbr Test Name
Clinical Assessment (CCA)
P B E TX O F
Mental Status
PHQ-9 Patient Health Questionnaire X X X D
POMS-SF** Profile of Mood States D D D X D
WAIS-IV Weschler Abbreviated Scale of Intelligence X
Phantom Pain
NPSI** Neuropathic Pain Symptom Inventory X D D D X D
VAS* Visual Analog Scale X D D D X D
BPI Brief Pain Inventory D D D D D
PsyP-Map Psychophysical Map of Sensation X D X D
PGIC Patient Global Impression of Change D D
Cortical Map fMRI functional Magnetic Resonance Imaging X X
With respect to the experiential dimensions of pain described by Jensen and
Karoly [25], the PHQ-9 and POMS-SF demonstrate changes in pain affect, PsyP-
Map and NPSI reflect changes to the pain quality and the VAS and nonoverlap of all
pairs (NAP) represent pain intensity. An additional aspect of interest is the subject’s
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perception of therapy effectiveness (measured by the PGIC), which does not fall un-
der the traditional dimensions of pain, but does provide an interesting perspective to
study effectiveness.
5.2.1 Data Collection
Aside from measurement frequency, methods for data collection are the same as
discussed in Chapter 4. Methods for several instruments (VAS, POMS-SF, NPSI)
are discussed previously (see subsection 2.3 for data collection and section 2.4 for
analysis methods). Methods involving BPI-IS are discussed in subsection 1.3.1 and
in subsection 2.4.2, since it was included as data that can be extracted by the EPI-
ONE Extraction Program (EEP). Below the remaining exploratory measures, PHQ-9,
PsyP-Map, and PGIC, are described.
PHQ-9
The PHQ-9 measures depression utilizing 10 questions to understand the subject’s
level of depression over the last 2 weeks. Questions follow the 9 criteria for depression
outlined in the 4th edition of the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-IV) [175]. Nine questions, each covering a particular symptom associated
with depression and ranging from 0 (“Not at all”) to 3 (“Nearly every day”), are used
to describe the degree of depression. Summing the nine responses gives a total score,
which indicates the degree of depression; it ranges from none/minimal (0-4) to severe
(20-27). The tenth question describes how difficult different aspects of daily living
have been, but does not contribute to the score of depression.
PsyP-Map
The psychophysical mapping questionnaire seeks to describe the quality and loca-
tion of non-painful phantom sensations. While some of the questions are very similar
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to those in other questionnaires, since the focus is on sensation, this instrument pro-
vides additional insight. Questions focus the frequency, quality, and impact to life
of phantom sensation as well as the size of, (involuntary and voluntary) movement
of, location of, and posture of the phantom. The question of frequency allows the
subject to respond with one of the four following options: “A few times a week”,
“A few times a day”, “A few times per hour”, or “All the time”. This is to better
understand how often sensations occur, as described in previous studies [9, 11]. The
quality of sensation can be described as itching, tingling, warmth, cold, electric sensa-
tions, movement, abnormal shape, abnormal position/posture, touching, and other.
If “other” is selected the subject is asked to describe the sensation. In regards to size
of the phantom (altered kinesthesia), the subject can respond by simply selecting,
“bigger”, “smaller”, or “no difference in size”. Subjects are asked to describe the vol-
untary and involuntary movements of the phantom; these are open ended since every
subject experience could vary so greatly. Location of the phantom is an indicator of
what areas are active. As stated in previous studies, amputees tend to lose sensation
in the proximal regions of the phantom, while distal sensation remains [10]. The
question of posture refers to fixed orientation of the phantom. Some predetermined
options are available; however, an open-ended response can also be submitted. Fi-
nally, the impact to life describes how troubling the non-painful phantom sensations
are in general (ranging from “not at all” to “very much”). In the PsyP-Map the
subject draws the location of the phantom limb as shown in Figure 5.1, where the
red area represents the subject’s response. This mapping can be used along with the
other PysP-Map responses to indicate changes in quality of sensation.
PGIC
The PGIC can is a useful instrument for understanding the perceived changes.
The questionnaire is administered in the final week of therapy, in the outcome visit,
and in the follow-up phase. The PGIC is a 7-point NRS ranging from 1 (“no change
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Fig. 5.1. The subject draws the location of the phantom in the PsyP-Map
Questionnaire.
or worse”) to 7 (“a great deal better”). In other studies the PGIC is asked a different
way, allowing responses to range from positive to negative effect [72,99,176]. Here the
PGIC is a one-sided measure, only able to capture improvement. For the subject-2
the traditional two sided PGIC was also administered along with the one sided PGIC.
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5.2.2 Methods of Analysis
As discussed in section 2.4, Cohen’s d for negative-facing scores is an important
tool for measuring effect. The thresholds for effect are -0.8 and 0.8 for large/strong ef-
fects and -0.5 and 0.5 for medium/moderate effects. For each instrument that requires
observing the change over time and does not have preset thresholds to observe, (i.e.
BPI-IS, NPSI, and POMS-SF) the above thresholds for Cohen’s d are utilized. Refer
back to Equation 2.3 for more details. The PHQ-9 has preset threshold for determin-
ing degree of depression as discussed below. The exploratory instruments (PHQ-9,
PsyP-Map, and PGIC) are merely observations and are not used to determine effect
size.
PHQ-9
Analysis of the PHQ-9 refers to the thresholds determined by a large sample study.
The general guidelines follow that of Table 5.2 generated from recommendations by
Kroenke et al. [175]. While the difference from the pre-therapy period to the post-
therapy period is noted, using the thresholds provides a more absolute measure of
depression.
Table 5.2. PHQ-9 Thresholds from Kroenke et al. provide a measure of
depression [175] before and after therapy.
Level of Depression PHQ-9 Score Range
None 0− 4
Mild 5− 9
Moderate 10− 14
Moderately Severe 15− 19
Severe 20− 27
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PsyP-Map
The PsyP-Map is not a validated questionnaire, but a compilation of several preva-
lent phantom sensation qualities noted in previous studies [9–11]. For the sake of
exploration and further understanding, analysis simply involves the comparison of
results without demarcation of significance. Items of interest lie in how the phantom
is perceived throughout the study and if it changes.
PGIC
The PGIC does not have a baseline measure to use for comparison. Rather, the
goal is to understand how the subject perceived change and whether or not changes
in other instruments are recognized by the subject’s impression of change over the
course of the therapy period.
5.2.3 Case Study Specific Details
Following the non-invasive electrical stimulation modality (niE), the IUPUI site
completed the protocol with two subjects. Subject one was an adult male who had
a left unilateral, transfemoral amputation as a result of diabetic neuropathy and mi-
crovascular disease. This subject was on a 300 mg maintenance dose of Gabapentin
three times per day. Subject-2 was an adult male who had a right unilateral, transtib-
ial amputation as a result of surgery. Enrollment in the study occurred > 2 years
post-amputation, with the stump in a stable phase for both subjects. Subject-1 is
also represented in Chapter 4 as one of the niE subjects.
5.3 Results and Discussion
Results are organized according to the dimensions of pain followed by the PGIC.
For subject-1 the results of therapy week-3 are not present because the subject did
not participate that week. Subject-1 attended two therapy visits in week-1, week-2,
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and week-4. Subject-2 attended therapy sessions all four weeks, missing one session
in the first week. In the following figures subject-1 results are reported in part A and
subject-2
5.3.1 Pain Intensity
The VAS and NAP (represented in Figure 5.2A and Figure 5.3A, respectively)
demonstrate a strong positive effect after the 4th week of therapy for subject-1. Av-
erage pain intensity over 24 hours dropped by more than 3 points from severe to
moderate and the effect size in terms of NAP rose above the strong, positive thresh-
old. The 0-hour and 1-hour control measures remain close to the moderate pain range
stretching into all three regions in most weeks. Looking at the temporal sequence of
results, the average 24-hour VAS drops week-to-week until the outcome visit, where
the pain intensity stretches back into the severe range. For the NAP, this weekly im-
provement is not seen. The range of week-to-week VAS results from therapy week-2
give a clue to why there is a discrepancy. In week-2 of therapy the maximum and
minimum score for average 24-hour VAS ranges over almost the entire VAS spectrum.
While there is improvement if looking only at the average VAS, the NAP method tells
a different story and the wider distributions of scores are accounted for. The 0-hour
and 1-hour measures of intensity fell in the none/weak to moderate, negative effect
range. This result is expected for the surface electrical stimulation method, as it can
cause minor discomfort during the therapy sessions.
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Fig. 5.2. In subject-1 (A) the primary outcome measure (average pain intensity over
24-hours) demonstrates a drop of average intensity from severe to moderate even
after missing a week of therapy. Subject-2 (B) has the opposite trend with an
increase in average pain intensity over 24-hours. Error bars represent the maximum
and minimum.
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Fig. 5.3. The primary outcome measure (average pain intensity over 24 hours)
demonstrates a strong, positive effect in subject-1 (A), even after missing a week of
therapy. Subject-2 (B) experienced moderate, negative effects of therapy.
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Subject-2 exhibits moderate negative effects of therapy. Figure 5.2B and Figure
5.3B show that the pain intensity increased throughout the therapy phase, and the
NAP extends into the moderate negative effect range. After ending therapy the NAP
returns to the no effect range. Compared to the results from subject-1, the ranges
of the in-week pain intensity scores are much tighter for subject-2. The 0-hour pain
intensity remains constant throughout the therapy phase; however, the 1-hour pain
intensity rises week to week.
5.3.2 Pain Affect
Pain affect is measured by the POMS-SF, BPI-IS, and PHQ-9 instruments. In
both subject-1 and subject-2, the POMS-SF shows limited response to therapy. This
is because nearly all subscale fall on the low end of the spectrum. Using the threshold
defined in subsection 2.6, two subscales show negative results and two subscales show
positive results throughout the course of the study for subject-1. As for subject-2
moderate, positive effects are demonstrated in both depression and vigor. Figure 5.4
depicts the response of mood states over the therapy period. For subject-1 the depres-
sion subscale falls near the minimum possible value in the pre-therapy phase, which
prevents observation of improvement. In this case a positive result is that all negative
facing subscales are at the minimum possible score throughout the therapy phase. Of
the negative facing subscales, only the confusion subscale reached a high enough value
in pre-therapy period to show positive effect (which was a strong, positive effect in
this case throughout the therapy period). Vigor presents a strong, negative result
throughout the therapy phase, but reverses to a strong, positive effect in the outcome
measure. These results are not particularly as expected, mainly because of the lack of
correlation among subscales. Baker et al. propose evidence of inverse correlation be-
tween vigor and depression scores as well as an inverse correlation of vigor and fatigue
scores [167]. However, the present data for subject-1 do not follow this expectation.
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Fig. 5.4. The POMS-SF provides insight to a subject’s mood state at each visit.
Subject-1 (A) shows mixed effects. Subject-2 (B) demonstrates positive effects in
depression and vigor. Error bars represent the maximum and minimum.* indicates
a moderate, positive effect, *! indicates a strong, positive effect, # indicates a
moderate, negative effect and #! indicates a strong, negative effect.
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A strong, negative change in vigor is not reflected by a strong, negative change
in depression or in fatigue. Furthermore, a strong, negative change in depression (in
the outcome measure) is counter to the trend in Baker et al. because of the strong,
positive change in vigor [167]. Subject-2 does demonstrate this correlation depression
and vigor. However, just like with subject-1 the other scores do not have a high
enough pre-therapy score to observe positive effects.
Two BPI-ISs (mood and sleep) demonstrate strong positive results in subject-1
(Figure 5.5A), when comparing the t-scores to p-scores according to the criteria in
Table 2.7. Other interference scales also show a decrease from pre-therapy; however,
the pre-therapy scores are not high enough to allow a sizable positive change. The
total score (average of the interference scales) presents a moderate, positive effect,
indicated by the drop of total pain interference. The total interference may be an
appropriate measure for comparison across subjects since every subject will likely have
a slightly different pain experience. Subject-2 (Figure 5.5B) experienced heightened
mobility and worsened effects for sleep. It seems as though the benefits were canceled
out in terms of over effect on the interference scale, as the total interference remained
close to the pre-therapy average throughout the therapy phase.
The reduction of interference in regards to walking for subject-2 provides a clue to
the possibility of external activities that could confound the results. During the study,
subject-2 was testing out a new prosthetic limb and increased his daily exercise. In
this regard his pain did not interfere as much as it had in the past; however, it begs
the question of whether the effects are from the new prosthetic or from the therapy.
This could also be said of the pain intensity measurements. It is reasonable to connect
the increased pain intensity with increased use of a prosthetic.
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Fig. 5.5. The BPI-IS and total score appear to be sensitive to therapy for subject-1
(A) and especially for subject-2 (B). The BPI-IS may provide additional insight into
the subject experience when looking at time-series correlations between BPI-IS and
VAS. Error bars represent maximum and minimum. * indicates a moderate, positive
effect, *! indicates a strong, positive effect, # indicates a moderate, negative effect
and #! indicates a strong, negative effect.
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The PHQ-9 provides insight to the longer term effects of therapy on mood, since
it is not asked on a weekly basis. Within the pre-therapy period, it is prompted two
times, in the pre-screen and entry phases. It is not reported again until the outcome
phase. Table 5.3 demonstrates the change from pre-therapy to post-therapy for both
subjects. In the Pre-Screen phase subject-1 exhibits moderately severe depression
and moderate depression in the entry phase. Post-therapy the PHQ-9 score dropped
below the threshold for mild depression, indicating a positive effect of therapy. This
drastic change in depression level seems to reflect the results demonstrated in the
pain intensity results. However, it is contrary to the POMS-SF results for depression.
Depression reported by POMS-SF subscale shows a strong, negative effect in the
outcome phase (with the score increasing from the pre-therapy). These results are
inconsistent considering the questionnaires are administered in the same day. The
likely explanation is that the POMS-SF reports on the subjects present state of mood,
while the PHQ-9 is intended to describe depression over the last two weeks. These
contrary results advocate for collecting additional data. As for subject-2 the PHQ-
9 results are consistent with the POMS-SF results reported for depression. The
moderate, positive results in the POMS-SF depression subscale correlate well with
the reduction from moderate to mild depression in the PHQ-9. However, if averaging
the pre-therapy measurements (to get a PHQ-9 score of 7.5 pre-therapy), subject-2
falls in the mild range for both pre-therapy and outcome.
5.3.3 Pain Quality
The NPSI demonstrates positive effects in several subscales for subject-1. Only
one subscale (evoked) did not reach a high enough level in the pre-therapy period to be
capable of demonstrating effect. The other five subscales demonstrate positive effects
at some point throughout the therapy phase. The paroxysmal, paresthesia/dysesthe-
sia, and total subscales exhibit strong, positive effects in week-2 of therapy. However,
after missing a week of therapy, the pain symptoms revert back toward the pre-
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Table 5.3. The PHQ-9 indicates the degree of depressive symptoms before and after
therapy.
Subject Clinical Assessment Phase PHQ-9 Score Level of Depression
Pre-Screen 16 Moderately Severe
Subject-1 Entry 13 Moderate
Outcome 3 None
Pre-Screen 4 None
Subject-2 Entry 11 Moderate
Outcome 6 Mild
therapy levels. To account for different perceptions and experiences of pain, the total
subscale is used for comparison among participants, as described in subsection 4.2.3.
Subject-2 experienced vast improvements for the burning symptom and moderate to
strong improvements for paresthesia. Pressing and paroxysmal had mixed effects and
the evoked symptom had moderate, negative effects toward the end of the therapy
phase. Overall, however, the total NPSI subscale demonstrates no effect of therapy
for subject-2.
The PsyP-Map provides a description of phantom sensation in general terms
throughout the study. In the pre-therapy period phantom sensations are described by
subject-1 as tingling, electric sensations, movement and abnormal position/posture
descriptions with sensations occurring between a few times a week and all the time.
The phantom limb is consistently described as smaller in size than the contralateral
limb (indicating some degree of telescoping). Furthermore, the subject described both
involuntary movement and the capability of moving the phantom at will. Involuntary
movements involved “swinging the leg side-to-side” and the feeling of “hav[ing] a shoe
on.” The movements at will are described as moving toes up and down, moving the
foot up and down at the ankle, and moving the limb side to side at the knee. An
unsolicited comment is noted several times in the pre-therapy period of the subject
not being able to “kick straight out”. Finally, the orientation of the phantom limb in
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Fig. 5.6. Several NPSI subscales show sensitivity to therapy. If subject-1 (A) had
not missed a week of therapy results may have been further improved. Subject-2
(B) reports positive effects in burning, but no effect overall. Error bars represent
the maximum and minimum. * indicates a moderate, positive effect, *! indicates a
strong, positive effect, # indicates a moderate, negative effect and #! indicates a
strong, negative effect.
the pre-therapy period is described as both normal and unusual, but most commonly
as knee bent.
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Immediately in the first week of therapy the subject began stating phantom sensa-
tions occur all the time. This lasted through the first two weeks. After missing week-3
of therapy the the subject selected the “a few times a week” option. Sensation quality
also changed when comparing therapy to pre-therapy. While the tingling sensation is
always present, the electric sensations, movement, and abnormal position/posture are
not selected as descriptors in the therapy phase. The size of the phantom remained
smaller throughout therapy (as it does throughout pre-therapy). Involuntary move-
ments changed after beginning therapy, where the leg no longer swings side-to-side.
One unsolicited comment from week-1 of therapy reflects this change, “I used to feel
[the phantom leg] swing back and forth by itself, but not now. Now, it just hangs
there.” Throughout the therapy phase movements at will also changed. Observing
unsolicited comments, the movement capability appeared to gradually change. In the
first week of therapy the subject describes the ability to “swing [the phantom] back
and forth.” He goes on to say, “I can move it up and down, like a kicking motion,
slowly. It hurts in my quads a little when I do it.” In week-2 of therapy the subject
states “I do not feel my leg as much as I feel my foot - overall.” At the outcome visit
the subject was able to swing side-to-side, wiggle toes, and kick forward. The rest-
ing orientation of the phantom limb was with the knee-bent throughout the therapy
phase.
Subject-2 described his phantom as tingling, feeling warmth, and electric sensa-
tions in the pre-therapy period and throughout the therapy period, and he noted
that the phantom sensations were present all of the time, or constantly. The phan-
tom would stay in a normal orientation, but was also uncomfortable for the subject.
In the pre-therapy period the subject noted being moderately troubled by his phan-
tom sensations. Once therapy began the subject selected “much” in response to how
troubling are the phantom sensations. In the final week of therapy, the response
was escalated to the highest possible response “very much troubled”, indicating the
phantom sensations became progressively more bothersome throughout the therapy
phase.
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5.3.4 Subject Perceptions
The PGIC indicates a lack of perceived change for subject-1. In both the final
therapy visit and in the outcome visit the subject submitted a score of 1 for the
PGIC, which in this study represents a result of no change or worse. While there
appears to be a change in quality of phantom sensation, as well as a positive change in
intensity, affect, and quality of pain, the subject’s impression of change is not positive.
Comparing this result to the unsolicited comments as described in subsection 5.3.3,
the subject recognized a change in the presentation of phantom sensation; however,
this evidently is not enough to elicit an overall positive impression of change.
Subject-2 received two versions of the PGIC; the first, as a one-sided questionnaire
and the second as a two-sided questionnaire. In response to the one-sided question-
naire the subject scored the PGIC as moderately better at the end of therapy and
as almost the same at the outcome visit. For the two-sided version of the PGIC the
subject selected much improved at the end of therapy and very much improved at
outcome. These results suggest that despite the mixture of positive and negative
effects recognized in several subscales, the subject perceived an overall positive effect
of therapy.
The results presented by the self-report data are compelling. Each subject had
a different experience with therapy. Subject-1 experienced a drop in pain intensity
(from severe to moderate) supported by the NAP analysis method, which shows
a strong, positive effect of therapy. Furthermore, the NPSI secondary instrument
demonstrates a reduction in several individual components of neuropathic pain symp-
toms. Exploratory measures such as the BPI-IS and PHQ-9 also demonstrate positive
effects of therapy, reducing the interference of pain in daily living and improving de-
pressive symptoms from moderately severe to none. On the other hand the vigor
subscale of POMS-SF and the PGIC contradict the positive effects, where the sub-
ject experiences a strong, negative effect in the vigor category and had an impression
of worse or no change from therapy. While subject-1 recognized a change in presen-
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tation of the phantom (as made evident from the PsyP-Map), the change is either
considered a negative change by the subject, or it is not strong enough to elicit a
positive impression.
Subject-2 reported an increase in pain intensity (from moderate to severe) and
moderate, negative effects in the NAP. The NPSI had several individual subscales
that were sensitive to therapy, but the total score remained consistent throughout
therapy. POMS-SF demonstrated an improvement in both depression and in vigor,
leaving the overall effect of therapy as inconclusive. The exploratory instruments
also had mixed results. BPI-IS showed an improvement in mobility (walking), but a
decrement in sleep, and the PHQ-9 on average remained constant (at mild depression).
The subject’s report of how troublesome his phantom sensations were throughout the
therapy phase got progressively worse, but the PGIC captured an overall positive
impression of change.
5.4 Conclusions
This case study demonstrates the feasibility of cognitively reinforced SES as a
therapy for PLP. Further research is needed to improve study power and to identify
effects of therapy with more confidence. The major limitation of the study as noted in
Chapter 4 is statistical power. Within each week of therapy subject-1 only attended
two therapy sessions and subject-2 attended 2-3 sessions per week. With a small
sample size of self-report data in each period, the effect of therapy is difficult to
describe. Furthermore, analyzing the results on a single subject basis reduces power.
We attempted to account for this in the VAS measurements by using the NAP analysis
method for single case research (SCR); however, even this has limitations. Parker and
Vannest suggest at least 13×13 comparisons, whereas the NAP analysis in the present
study is under that threshold [170]. Future studies should improve analysis of study
outcome measures through addressing both concerns. Ideally, a study would involve
a take home system and the capability of participants to complete questionnaires
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from home through an online system. As is evident from the present study, subject
non-compliance is a notable hurdle. While the study criteria require attendance of
3− 5 therapy sessions per week, subjects of the present case attended on 2-3 sessions
per week, and subject-1 skipped one week entirely. Had participation been more
convenient, this non-compliance may have been avoided. It is inevitable that study
participants will encounter stimuli and experience circumstances that can effect the
study results. Whether it is dealing with a family crisis or experimenting with a new
prosthetic, pain, mood, and daily life are inherently linked. Remarkably, several self-
report questionnaires demonstrate some level of effect throughout therapy, despite
these hurdles. However, the question that remains is whether or not the effects are
a result of the therapy. In order to establish a more powerful argument either for or
against the effectiveness of the therapy, the clinical team hopes to collect more data
from additional subjects.
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6. SUMMARY
6.1 Review of the Present Work
Chapter 1 discussed the recent trends in amputation and post-amputation pain
(PAP). While amputation often extends life, preventing debilitating problems for
individuals suffering from dysvascular disease for example, it can also present entirely
new challenges to the patient. Amputation is on the rise according to Ziegler-Graham
et al. [4], which means that post-amputation pain is becoming more and more relevant.
The lack of a standard of care for various aspects of PAP is explained by the sheer
lack of understanding of the underlying mechanisms [126]. Some aspects can be
explained, such as neuromata related pain; however, more complicated aspects such
as phantom limb pain (PLP) are far from being explained by a specific mechanism.
Several mechanisms with origins at every level of the nervous system from cortical
to peripheral are offered, but proving a mechanism is an entirely different matter.
Relying on self-report questionnaires and intrinsically subjective data makes the study
of pain and pain mechanisms complicated and turbid. For example an individual’s
milieu has significant effects on pain tolerance [95], and this factor cannot be easily
accounted for when attempting to establish a standard therapeutic method.
Recent efforts by the EPIONE consortium have attempted to isolate a therapy
that offers relief to PAP, with a focus on PLP. Utilizing sensory feedback via electrical
or mechanical stimulation to reinforce imagined movement of the phantom is the
focus of Chapter 2 and Chapter 4. A pilot study of several possible therapy methods
offers insight into the expected feasibility of implementing each modality. Preliminary
analysis of primary and secondary outcomes demonstrates an overall positive effect
of therapy after just four weeks. However, additional effort is required to increase
sample size for each modality to strengthen the statistical evidence.
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In the midst of designing, initiating, and running the clinical trial, software was
developed to reduce the opportunities for error and speed up the post-processing of
the self-report data. This is the focus of Chapter 3. The software was designed with
the primary and secondary instruments of the EPIONE consortium clinical trial in
mind. In addition, several other design requirements were considered to ensure the
softwares usability, accuracy, and precision. The software was validated using an
example dataset, and subjected to a test of robustness with the pilot data presented
in Chapter 4. Seeing that the software was capable of handling data of various shapes
and sizes; it was considered ready-to-use.
The case study of surface electrical stimulation presented in Chapter 5 demon-
strates mixed effects overall, and presents several challenges of translational research.
According to the study’s primary measure of pain intensity, pain reduced over the
course of the therapy phase in one subject and increased in another subject. In
addition, the subjects had differing overall impressions of change; one experienced
no change from therapy, while the other reported a perceived improvement. These
results give some insight into why translational research of pain is challenging. For
example a single subject reported both a reduction of pain intensity and an overall
impression of no change. It is impossible to isolate an individual from outside influ-
ences. The drop in depression seen in the patient health questionnaire (PHQ-9) of the
case study could be from external experiences having nothing to do with the study.
The same could be said of pain intensity. These issues illuminate why large sample
sizes and randomized controlled trials are necessary for establishing the effectiveness
of a therapy.
6.2 Limitations
The major limitation of the pilot study described in Chapter 4 and the case
study described in Chapter 5 is sample size for both number of subjects and number
of observations for each instrument. While these demonstrate the feasibility of the
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suggested therapy methods, further study is required to prove the effectiveness. In
addition, several instruments used in the present study utilize reference populations
that are not necessarily representative of the study population for describing the
degree of effect. Furthermore, some of the instruments used in the present study
do not appear to be sensitive to the emotional and psychological aspects of pain
experienced by an amputee. For example, the POMS-SF results largely fell on the
bottom of the spectrum in most cases.
6.3 Future Work
In future work, studies should focus on improving the methods for collecting data
and designing a study that minimizes the effects and opportunities of subject non-
compliance. As discussed in Chapter 5, one subject of the case study skipped an
entire week of therapy, making data interpretation difficult. Future studies should
minimize time in the clinic for the subject by implementing a take home system. Self-
report questionnaires should be administered through an easily accessible website or
through a smartphone application. In both cases there are standards for protect-
ing health data, such as Fast Healthcare Interoperability Resources. Secondly, the
therapy should be updated to a take home system. According the code of federal
regulations title 21 section 882.5890, transcutaneous electrical nerve stimulators for
pain relief are class II devices [177]. Take home stimulators are available in the U.S.
market. Adapting to a take home system and requiring only weekly visits instead
of daily, coupled with online administration of self-report questionnaires would sig-
nificantly reduce the amount of effort required to participate in the trial and likely
increase participation. There is still much to do to understand the effectiveness of the
proposed therapy method, but progress is made one step at a time, and this study
serves as a small step toward alleviating PLP.
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6.5 Project Related Contributions and Activities
Shortly after collecting the pilot data discussed in Chapter 4, members of the
EPIONE consortium submitted a conference proceeding on the clinical study design,
to which I had the opportunity to contribute [166]. This conference paper highlighted
the methods for implementing a clinical trial. Throughout the EPIONE project, I
had the opportunity to contribute to project deliverables and other project related
documentation. The two most significant deliverables to which I helped author were
EPIONE Project Deliverable 1.3, “Collected results and experiences from first round
of clinical trials,” and EPIONE Project Deliverable 1.4, “Refined clinical protocol for
delivering invasive / non-invasive nerve sensory feedback.” In addition to the deliv-
erables, I drafted a document which interpreted the manual for the psychophysical
platform into clinical work instructions, which proved to be very useful at the IUPUI
clinical site.
The EPIONE Extraction Program (EEP) and EEP - Group Analysis Module
(GAM), are the major contributions to the EPIONE project. The development of
these software tools, took a process that previously required days for each clinical
subject and reduced it to minutes or even seconds. Furthermore, data accuracy was
also strengthened by reducing the opportunity for human error in results handling.
These programs are just a small piece of all the technology developed in the EPIONE
project, but it serves an important purpose, saving time and money and improving
data quality.
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Participation in the EPIONE consortium took me across the globe. In the summer
of 2015 and summer of 2016, I traveled to Aalborg, Denmark, and Lund, Sweden
for the EPIONE General Assemblies. In Lund I introduced an early version of the
EEP, and received critical feedback for the development of the software tool. These
experiences not only improved my understanding of the project, but also improved
on intangible, soft skills, by interacting with team members from other cultures and
backgrounds.
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A. THE EPIONE EXTRACTION PROGRAM USER
GUIDE
A.1 Introduction and Purpose
The purpose of the EPIONE Extraction Program (EEP) is to extract the raw data
generated by the EPIONE Psychophysical Platform (PsyP) and conduct the initial
analysis on the psychophysical data. This program compiles, analyzes, and tabulates
the results for a subject of the EPIONE consortium clinical study. This user guide
is to be used with EEP software version 1.0.x (v1.0.x) and has been validated up
to version 3.1.15 of the PsyP. The EEP can be used with four psychophysical data
types generated during the EPIONE common clinical protocol (CCP); this includes
the brief pain inventory (BPI), neuropathic pain symptom inventory (NPSI), profile
of mood states - short form (POMS-SF), and visual analog scale (VAS).
A.2 Operation
A.2.1 Installation
Download the EPIONE Data Extraction installer. You will need admin rights to
complete the installation process. After you begin the installer will ask where you
want to save the program. If you do not have MATLAB R© Runtime already installed
on your machine the installer will proceed by adding this to the installation process.
The final steps are accepting the terms of the MATLAB R© Runtime License agreement
and initiating installation.
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A.2.2 Getting Started
The EEP allows the the data analyst to compile and analyze a subject’s data
following the completion of the EPIONE CCP. Figure A.1 shows version 1.0.0 of the
software’s front panel. The organization of the program is mostly in order of work
flow. This subsection will go through, step-by-step, how to use the program. While
these steps can be completed in any order, the order is meant to be intuitive for the
user.
Fig. A.1. The EPIONE Extraction Input Panel at startup
The basic workflow involves identifying the working directory, specifying the Study
ID, selecting the username.xml file, pointing to the data directory, picking the data
to be saved, and selecting the study location. Throughout the process workflow, the
user can select the button with the question mark next to the area where help is
needed and a new window will open with some helpful details.
Step 1: Choose Working Directory
Clicking on Choose Working Directory will open a new window. This can be used
to select the folder in which to save the output file; this also serves as home directory
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for the rest of the processing. Each time the user attempts to open a file, the program
will use the selected working directory as the starting point.
Fig. A.2. Choosing the working directory where output data will be saved.
It is recommended not to use the desktop as the working directory. Depending on
the options selected, up to 13 files can be generated, including one Excel R© file, one
mat-file, one log-file for debugging, five MATLAB R© figure files, and 5 scalable vector
graphic (SVG) figure files. In Figure A.2 a file called PsyP Analysis in the subject’s
natural Psychophysical Platform data folder.
Step 2: Input Study ID
The study ID is very important for linking a subject’s psychophysical data to
his/her fMRI data. The study ID should be the same as what was given during the
fMRI, which is not necessarily the ID that is given by the Psychophysical Platform.
It is recommended for the ID to be a random string of 6 alphanumeric characters to
de-identify the data. If necessary use a separate document to keep track of study IDs
generated by the Psychophysical Platform and the ID for data analysis. Clicking on
the Study I.D. brings up the window shown in Figure A.3.
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Fig. A.3. Specifying the subject I.D.
After the window pops up, the user enters the study ID, and clicks OK, the input
panel will display the user entered study ID. If the ID is incorrect, simply click the
Study I.D. button again and re-enter the appropriate study ID.
Step 3: Select Username.xml File
The username.xml file is found within the subject specific folder. An example
of the typical file path for this file is: /ProgramData/EPIONE/Subjects/z01cc/,
where z01cc should be replaced by the subject’s Psychophysical Platform username.
Note the ProgramData directory is typically hidden in the windows C-drive. The
username.xml file for this example case would be z01cc.xml. Clicking the Select
username.xml button on the input panel opens another window to browse to the
appropriate directory. Note, there are other, similar xml-files also existing in this
directory; however, only the z01cc.xml file should be selected. If the wrong file is
selected simply click the Select username.xml button again and select the appropriate
file. Only one file can be selected at any given time. If the subject folder structure is
maintained, the next step is simplified. The EEP will recognize if the data directory
exists and will automatically fill in the next field. If this data directory is correct and
is the only data directory Step 4 can be skipped.
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Step 4: Point to Data Directories
Just like with choosing the working directory, pressing the Point to data directo-
ries button will open a window to browse from the working directory to the folder
containing the subject’s data (or the data directory). If your data is in separate
folders, multiple directories can be entered, one at a time, by clicking the Point to
data directories button and pointing to each folder individually. Each data directory
will be listed in the input panel window. Psychophysical Platform data is typically
found in .../z01cc/Questnr directory. In most cases all of the subject’s data should
be contained within this folder. Data files have the .mat extension. Each selected
directory will be listed in the window to the right of the Point to data directories
button. If an incorrect directory is selected, select the directory in the list of data
directories and click clear. This will remove the selected directory. After selecting
the username.xml file and pointing to the data directories, the input panel should
resemble Figure A.4.
Fig. A.4. Selecting the subject specific data files for processing
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Step 5: Select the Data to be Saved
Select the data you want to save by checking the box next to each measure type.
Toggling the All Data box will select or deselect all four data measure types (BPI,
NPSI, POMS, and VAS). These can be requested independently if desired. Note, that
the VAS checkbox will also save the Nonoverlap of All Pairs (NAP) data. Further-
more, for the sake of convenience, the EEP can generate preliminary figures in the
form of scalable vector graphics (SVGs) and MATLAB R© figure files (FIGs). If the
user prefers to create his or her own figures, the average, maximum, and minimum
values for each questionnaire type can be saved to a mat-file, but can also be found
within the Excel R© output file. For every measure selected by the user, the statis-
tics are saved for each analysis period (pre-therapy, therapy week-1, etc.). Note, for
group analysis in the EEP - Group Analysis Module, the data should be saved in the
mat-file format. See Appendix B for more details.
Step 6: Specify Location of Study
There are two options for this drop down menu; the user must select one to
continue to processing. If the questionnaires were administered in Danish, the user
should select Denmark as the location of study; otherwise, the user should select
Other Site. Upon completing Step 6, the input panel should resemble Figure A.5.
Step 7: Create Excel R© Sheet
To create the output file, select Create Excel R© sheet. Depending on the amount of
data for a given subject, the data requested for processing by the user, and the system
specifications of the machine processing the data, output files should be available in
just a few minutes. Observe the progress bar during processing for reference. This will
create an .xls file in the working directory (selected in step 1), in addition to a log file
(used for debugging), and additional files at the user’s request (such as figures or mat-
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Fig. A.5. The input panel prior to processing data
file). The file name will be displayed in the successful extraction pop up window. All
data files will be named in the following format: PsyPdata studyID ABCDEF.xls,
where ABCDEF is a string of six random, alphanumeric characters. Figure A.6
demonstrates the pop-up window that is displayed if extraction is successful. Once
this window is displayed the user can close the program and investigate the output
files or continue processing another subject’s data.
Fig. A.6. Successfully extracting data is indicated by the EEP
Note, upon clicking Create Excel R© sheet, the button is disabled until the EEP
has completed processing the requested data. This is to protect the integrity of the
data and to avoid interrupting the software. While every effort has been made to
anticipate and prevent user-errors, some errors are simply unpredictable. Should an
129
unanticipated error occur, the Create Excel R© sheet button may or may not be re-
enabled. If it is not re-enabled the button will still visibly toggle, but processing will
not begin (as would be indicated by a progress bar). To alleviate this issue, simply
close and re-open the EEP.
Step 8: Exit
You may exit the EEP at any time by clicking the Exit button, or clicking the
red X button in the corner of the window. Note, because of the brevity of entering
the file locations, there is no method of saving entries in this program, so exiting will
lose any settings. However, The log-file generated during processing contains a list
of all of the settings selected. This allows the user to review or even repeat previous
extractions if necessary.
A.2.3 Output Files and Analysis
The output Excel R© file has several tabs/sheets of data. Because of restrictions
of MATLAB R©, Excel R©, and computer operating systems, three empty sheets will
appear at the front of each output file. These can be deleted at any time. The first
relevant sheet is Results. This displays the final results calculated by the program
for the primary and secondary instruments. For VAS the scores are displayed as
NAP scores. For NPSI and POMS, the scores are displayed as difference scores. For
this sheet and all others, only the data selected in the input panel will be available.
Furthermore, if a measure is not selected (e.g. if the VAS checkbox is not checked),
the measure specific sheets will not be available in the output file (e.g. NAP tables).
Following the Results sheet is the Tables sheet. This contains the average, min-
imum, and maximum values for a given period for each selected score. Periods are
broken up into the following groups: Pre-therapy, Therapy week-1, Therapy week-
2, Therapy week-3, Therapy week-4, Outcome, and Follow-Up. In the case of the
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NAP scores, the Outcome and Follow-Up phases are combined into the Post-Therapy
period score. This is to take advantage of the multiple comparisons.
NAP tables are provided for each of the three VAS measures (0-hour, 1-hour,
24-hour). The scores displayed in the Results sheet are calculated by averaging the
NAP in each therapy week (or post-therapy period). The Schedule sheet shows the
dates for the subject entering each phase. If the program could not find the date,
DNE (Does Not Exist) is displayed. The remaining sheets simply display the data
in different formats. The Binned format separates the data into column groups for
the sake of the readability. This allows the reader to understand how the data was
organized for analysis at a quick glance. This should be used to evaluate how scores
were broken up to get the week to week effect size displayed in the Results sheet. The
data is also displayed in the Raw sheets. These contain the timestamp and scores (for
BPI and VAS) or timestamp, subscores, and question scores (for NPSI, and POMS).
The mat-file contains repeated information from the Tables sheet of the Excel R©
file. The purpose of the mat-file is to get the data in an easily accessible format.
Included in the mat-file are the average, maximum, and minimum for each instrument
for each period as described previously. In addition two other variables containing
the difference between the average and minimum for each index and for the difference
between the average and maximum for each index allow one to quickly create bar
graphs with max-min error bars in MATLAB R©.
The effect size can be calculated by referring to Table A.1 and Table A.2. These
effect size thresholds are elaborated on in section 2.4, which discusses the background
of how results are calculated as well as these limits for effect. In regards to the NAP
the limits are for a two sided test of effect per the recommendations of Parker and
Vannest [170].
The thresholds for effect size for the secondary measures (NPSI and POMS-SF)
and for the BPI interference scale (BPI-IS) exploratory measure are in Table A.2.
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Table A.1. The VAS-NAP thresholds for measuring effect size.
NAP Thresholds Effect
0 − 0.07 Large/Strong Negative
0.08− 0.33 Medium/Moderate Negative
0.34− 0.66 None
0.67− 0.92 Medium/Moderate Positive
0.93− 1 Large/Strong Positive
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B. THE GROUP ANALYSIS MODULE USER GUIDE
B.1 Introduction and Purpose
The purpose of the EPIONE Extraction Program - Group Analysis Module (EEP-
GAM) is to generate group results from subject data created by the EEP. This module
compiles, runs preliminary analysis, and tabulates results for a group configured by
the user. This user guide is to be used with the GAM software version 1.0.x (v1.0.x)
and has been validated up to version 3.1.15 of the PsyP. The GAM can be used with
the four psychophysical data types generated during the EPIONE common clinical
protocol (CCP); this includes the brief pain inventory (BPI), neuropathic pain symp-
tom inventory (NPSI), profile of mood states - short form (POMS-SF), visual analog
scale (VAS), and Nonoverlap of all pairs (NAP).
B.2 Operation
B.2.1 Installation
No installation is needed to run the GAM. This module runs in the MATLAB R©
Standard Suite, provided by MathWorks, Inc.
B.2.2 Getting Started
To begin simply download the module specific MATLAB R© files and click the files
to open the input panel. The GAM allows the the data analyst to compile and analyze
group data following the completion of the EPIONE CCP and initial processing in
the EEP. Figure B.1 shows version 1.0.0 of the software tool’s front panel. The
organization of the program is mostly in order of work flow. This subsection will go
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through, step-by-step, how to use the GAM. While these steps can be completed in
any order, the order is meant to be intuitive for the user.
Fig. B.1. The Group Analysis Module Input Panel at startup
The basic workflow involves specifying the Subject Codes specifying the Group
IDs, selecting the subject data, picking the data to be saved, and selecting a save
directory.
Step 1: Adding Subjects to the Workspace
The table in the workspace is for creating the analysis table. The analysis table
specifies the subject codes, group IDs, and location of the subject data. To begin
filling in the analysis table click on the cell below Subject Code. This allows the user
to type in the subject code, which can be alphanumeric. To add the group name for
a subject click on the corresponding cell under the Group ID column and type in the
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group ID. The group IDs are case-sensitive and can be alphanumeric. An example of
this is demonstrated in Figure B.2.
Fig. B.2. Users can add subject codes and group IDs by typing into the analysis
table.
To finish adding a subject to the analysis table, select the corresponding cell under
the Mat File column and click the Add Subject Data button. A separate window pops
up to select the subject’s mat-file generated during processing in the EEP.
Add or Remove Subjects
Additional subjects can be added to or removed from the analysis table by using
the Add Subject Below or Add Subject Above buttons, which is demonstrated in Figure
B.3. If you want to remove a subject, select a cell in the subject line of the analysis
table and select the Delete Subject button.
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Fig. B.3. Adding and removing subjects from the group analysis table is simple
with the navigation buttons.
Step 3: Select the Data to be Saved
Select the data you want to save by checking the box next to each data type.
Toggling the All Data box will select or deselect all four data types (BPI, NPSI,
POMS, and VAS). These can be requested independently, if desired. Note, that the
VAS checkbox will also save the NAP data. For the sake of convenience, the GAM
can generate preliminary figures in the form of scalable vector graphics (SVGs) and
MATLAB R© figure files (FIGs) by selecting the Figures format. If the user prefers to
create his or her own figures, the group average, maximum, minimum, standard devia-
tion, and n values for each questionnaire type can be saved to a mat-file. The mat-file
also contains the average, maximum, and minimum for each subject as well. This
information can also be found within the Excel R© output file if the Excel R© checkbox is
selected. Toggling the All Formats selects or deselects all of the output formats. For
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every measure selected by the user, the statistics are saved for each analysis period
(pre-therapy, therapy week-1, etc.).
Step 4: Specify the Save Directory
It is recommended not to use the desktop as the working directory. Depending
on the options selected, up to 64 files can be generated for each group specified in
the analysis table, including one Excel R© file, one mat-file, 31 FIGs, and 31 SVGs. In
Figure B.4 a folder called GroupResults is selected as the location for saving output
files.
Fig. B.4. All information is entered into the GAM input panel and the user is ready
for processing.
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Step 5: Process Data
To create the output file, select Process Data. Depending on the amount of data
for a given subject, the data requested for processing by the user, and the system
specifications of the machine processing the data, output files should be available
in just a few minutes. Observe the progress bar during processing for reference.
The GAM will create files at the user’s request in the following order. Excel R© files
are created first, mat-files second, and figures last. Data types are also sequential:
BPI, NPSI, POMS, VAS, NAP. Before moving on to the next format or data type,
the module will process each group. Once the module is done processing data a
window pops up stating group analysis is successful. All data files will be named
in the following format: PsyPdata Group GroupID DataType ABCDEF.xls, where
ABCDEF is a string of six random, alphanumeric characters. Figure B.5 demonstrates
the pop-up window that is displayed if group analysis is successful. Once this window
is displayed the user can close the program and investigate the output files or continue
processing another subject’s data.
Fig. B.5. Successfully extracting data is indicated by the GAM.
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Step 6: Saving and Loading the Workspace (optional)
Before or after processing the workspace can be saved for future use. To save the
workspace click the Save workspace... button. The workspace is saved as a mat-file.
To load the workspace click the Load the workspace... button and select the mat-file
previously saved.
Step 7: Exit
You may exit the EEP at any time by clicking the Exit button, or clicking the
red X button in the corner of the window. Note, if the workspace is not saved there
is no way to recover work.
B.2.3 Output Files and Analysis
The output Excel R© file has several tabs/sheets of data. Because of restrictions
of MATLAB R©, Excel R©, and computer operating systems, three empty sheets will
appear at the front of each output file. These can be deleted at any time. The first
relevant sheet is Results. This displays the final results calculated by the GAM for
the BPI, NPSI, POMS-SF, and NAP. For the primary instrument, VAS, the effect
is displayed as NAP scores. For BPI, NPSI and POMS, the scores are displayed as
difference scores. For this sheet and all others, only the data selected in the input
panel will be available. Furthermore, if a measure is not selected (e.g. if the VAS
checkbox is not checked), the measure specific sheets will display N/A in the Excel R©
file.
Following the Results sheet are the data type specific sheets. These sheets contains
group data along with the average, minimum, and maximum values for each subject
in the group. The group data saved in this sheet is the average, minimum, maximum,
standard deviation, and n. The n table shows the number of subjects used for each
group score. This is useful especially if a subject is missing data. Periods are broken
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up according to the following time periods: Pre-therapy, Therapy week-1, Therapy
week-2, Therapy week-3, Therapy week-4, Outcome, and Follow-Up. In the case of the
NAP scores, the Outcome and Follow-Up phases are combined into the Post-Therapy
period score. This is to take advantage of the multiple comparisons.
The mat-file contains the same information as the Excel R© file. The purpose of
the mat-file is to get the data in an easily accessible format. Included in the mat-
file are the average, maximum, and minimum for each instrument for each period as
described previously.
The effect size can be calculated by referring to Table A.1 and Table A.2. These
effect size thresholds are elaborated on in section 2.4, which discusses the background
of how results are calculated as well as these limits for effect. In regards to the NAP
the limits are for a two sided test of effect per the recommendations of Parker and
Vannest [170].
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C. EPIONE EXTRACTION PROGRAM CHANGE LOGS
C.1 EPIONE Extraction Program Change Log
C.1.1 Preface
The EPIONE Extraction Program (EEP) Change Log tracks changes for released
versions of the EEP. EEP versions are in the M.ma.mb format where M denotes
major changes to the software, ma denotes minor changes to the software that evoke
a different user experience, and mb specifies minor changes to the software that do
not change how the user interacts with the software, i.e. minor backend changes.
Major changes could involve several additional features at once, significant bugs, etc.
Examples of minor changes include bugs that do not affect data quality, background
features to optimize the program, background features for system integration, or
additional features that do not significantly alter the user experience. Importance
level is determined based on the detectability, the stage of the project, effects on data
quality, and how many clinical sites are affected. Affected parties refers to which
clinical sites are affected by the change.
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C.1.2 v1.0.2 - Currently Released Version
Updates from Previous Version
Changed cutoff date for POMS data import correction. Previous versions use
v3.1.15 of the psychophysical platform as the cutoff date when it should be v3.1.17.
This issue stems from known software differences in the psychophysical platform for
data entry and interpretation. POMS questions are supposed to range 1-5 and in some
scenarios 1s were encoded as 0s. For Danish POMS the values ranged 0-4 instead of
1-5. This was corrected in v3.2.0 of the psychophysical platform.
Importance Level
Moderate Importance.
Effects on Data Quality or Accuracy
POMS data from previous versions is effected for all sites only if data collected
after v3.1.15 and before v3.2.0 of the Psychophysical Platform. Otherwise, data is
unaffected.
Recommended Activities
Update to latest version. Rerun POMS data if data collected after v3.1.15 and
before v3.2.0. Otherwise, no action required.
Affected Parties
All
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C.1.3 v1.0.1 - Retired Version
Updates from Previous Version
Added NAP data to mat-file output. This allows data to be passed into the group
analysis module.
Importance Level
Low Importance.
Effects on Data Quality or Accuracy
None.
Recommended Activities
Update to latest version. If you want to run group analysis this version is re-
quired.
Affected Parties
All.
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C.1.4 v1.0.0 - Retired Version
Updates from Previous Version
First release.
Importance Level
N/A
Effects on Data Quality or Accuracy
N/A
Recommended Activities
N/A
Affected Parties
N/A
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C.2 Group Analysis Module Change Log
C.2.1 Preface
The EPIONE Extraction Program - Group Analysis Module (GAM) Change Log
tracks changes for released versions of the GAM. GAM versions are in the M.ma.mb
format where M denotes major changes to the module, ma denotes minor changes to
the software that evoke a different user experience, and mb specifies minor changes to
the software that do not change how the user interacts with the software, i.e. minor
backend changes. Major changes could involve several additional features at once,
significant bugs, etc. Examples of minor changes include bugs that do not affect data
quality, background features to optimize the program, background features for system
integration, or additional features that do not significantly alter the user experience.
Importance level is determined based on the detectability, the stage of the project,
effects on data quality, and how many clinical sites are affected. Affected parties
refers to which clinical sites are affected by the change.
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C.2.2 v1.0.0 - Currently Released Version
Updates from Previous Version
First release.
Importance level
N/A
Effects on Data Quality or Accuracy
N/A
Recommended Activities
N/A
Affected Parties
N/A
